

APL

8E 3-31-04




04037264

CORVEL

PROCESSED


JUL 09 2004

THOMSON
FINANCIAL




Revenue (in millions)

Net Income (in millions)




Earnings Per Share (in dollars)

Cash (in millions)



Return on Equity (%)

Q4 Weighted Shares (in millions)



UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

**FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

- ☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended March 31, 2004

OR

- ☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to

Commission File Number 0-19291

CorVel Corporation

(Exact name of registrant as specified in its charter)

Delaware

*(State or other jurisdiction of
incorporation or organization)*

**2010 Main Street, Suite 600,
Irvine, California**

(Address of principal executive offices)

33-0282651

*(I.R.S. Employer
Identification Number)*

92614

(Zip Code)

Registrant's telephone number, including area code:

(949) 851-1473

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common Stock

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes ☒ No ☐

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the Registrant's most recently completed second fiscal quarter:

As of September 30, 2003, the aggregate market value of the Registrant's voting and non-voting common equity held by non-affiliates of the Registrant was approximately \$171,259,000, based on the closing price per share of \$35.51 for the Registrant's common stock as reported on the Nasdaq National Market on such date multiplied by 10,583,191 shares of the Registrant's common stock which were outstanding on such date. For the purposes of the foregoing calculation only, all of the Registrant's directors, executive officers and holders of ten percent or greater of the Registrant's outstanding common stock have been deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

Indicate the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date: As of May 31 2004, there were 10,587,086 shares of the Registrant's common stock, par value \$0.0001 per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Information required by Items 10 through 14 of Part III of this Form 10-K is incorporated herein by reference to portions of the Registrant's definitive proxy statement for the Registrant's 2004 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended March 31, 2004. Except with respect to the information specifically incorporated by reference in this Form 10-K, the Registrant's definitive proxy statement is not deemed to be filed as a part of this Form 10-K.

CORVEL CORPORATION
2004 FORM 10-K ANNUAL REPORT
TABLE OF CONTENTS

		<u>Page</u>
PART I		
Item 1.	Business	2
Item 2.	Properties	19
Item 3.	Legal Proceedings	19
Item 4.	Submission of Matters to a Vote of Security Holders.....	19
PART II		
Item 5.	Market for the Registrant's Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities	19
Item 6.	Selected Financial Data	20
Item 7.	Management's Discussion and Analysis of Financial Condition and Results of Operations	20
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 8.	Financial Statements and Supplementary Data	20
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	20
Item 9A.	Controls and Procedures	20
PART III		
Item 10.	Directors and Executive Officers of the Registrant	21
Item 11.	Executive Compensation	21
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	21
Item 13.	Certain Relationships and Related Transactions	21
Item 14.	Principal Accountant Fees and Services	21
PART IV		
Item 15.	Exhibits, Financial Statement Schedules and Reports on Form 8-K	22

(This page intentionally left blank)

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. Investors should consider these factors before deciding to make or maintain an investment in our securities. This report includes forward-looking statements including, but not limited to, the statements about our plans, strategies and prospects under the headings "Business" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Words such as "anticipates", "expects", "intends", "plans", "believes", "seeks", "estimates", "may", "will" and variations of these words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on management's current expectations, estimates and projections about our industry, management's beliefs, and certain assumptions made by management, and we can give no assurance that we will achieve our plans, intentions or expectations. Certain important factors could cause actual results to differ materially from the forward-looking statements we make in this report. Representative examples of these factors include (without limitation):

- general industry and economic conditions;
- cost of capital and capital requirements;
- competition from other managed care companies;
- the Company's ability to renew and/or maintain contracts with its customers under existing terms or restructure these contracts on terms that would not have a material negative impact on the Company's results of operations;
- the ability to expand certain areas of the Company's business;
- shifts in customer demands;
- the ability of the Company to produce market-competitive software;
- changes in operating expenses including employee wages, benefits and medical inflation;
- changes in regulations affecting the workers' compensation, insurance and healthcare industries in general;
- dependence on key personnel;
- possible litigation and legal liability in the course of operations;
- and the continued availability of financing in the amounts and at the terms necessary to support the Company's future business.

The section entitled "Risk Factors" set forth in this report discusses some of the other important risk factors that may affect our business, results of operations and financial condition. The factors listed above and the factors described under the heading "Risk Factors" and similar discussions in our other filings with the Securities and Exchange Commission are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could have material adverse effects on our future results. The forward-looking statements included in this annual report on Form 10-K are made only as of the date of this annual report. We expressly disclaim any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.

PART I

Item 1. *Business.*

Introduction

CorVel Corporation ("CorVel" or the "Company") is an independent nationwide provider of medical cost containment and managed care services designed to address the escalating medical costs of workers' compensation and other healthcare benefits, primarily coverage under group health and auto policies. The Company's services are sold as bundles of solutions directed to managing claims, care, networks, reimbursements and settlements. They include automated medical fee auditing, preferred provider networks, out-of-network/line item bill negotiation and repricing, utilization review and utilization management, medical case management, vocational rehabilitation services, early intervention, Medicare Set-Asides and life care planning, and a variety of directed care services including independent medical examinations, diagnostic imaging, transportation and translation, durable medical equipment and physical therapy. Such services are provided to insurance companies, third-party administrators ("TPAs"), and self-administered employers to assist them in managing the medical costs and monitoring the quality of care associated with healthcare claims.

The Company was incorporated in Delaware in 1991, and its principal executive offices are located at 2010 Main Street, Suite 600, Irvine, California, 92614. The Company's telephone number is 949-851-1473.

Fiscal 2004 Developments

Acquisition of Scan One

In June 2003, the Company acquired Portland, Oregon based Scan One, a provider of scanning, optical character recognition and document management services. The Company believes that this acquisition will expand its existing office automation service line and the Company expects that all its offices will begin to sell scanning and document management, the services previously sold by Scan One. The Company also intends to add scanning operations to a number of the Company's larger offices.

Company Stock Repurchase Program

During fiscal 2004, the Company continued to repurchase shares of its common stock under a plan approved by the Company's Board of Directors. In April 2002, the total number of shares authorized to be repurchased was increased to 6,100,000 shares, adjusted for the three-for-two stock split in the form of a dividend in August 2001. During fiscal 2004, the Company spent \$12.2 million to repurchase 342,121 shares of its common stock. Since commencing this program in the fall of 1996, the Company has repurchased 5,573,428 common shares through March 31, 2004, equal to approximately 34% of its outstanding stock, at a cost of \$96 million. These repurchases were funded from the Company's operating cash flows. See "Issuer Purchases of Equity Securities" below for more information on the Company's purchase of shares of its common stock during the fourth quarter of Fiscal 2004.

Industry Overview

Workers' compensation is a federally mandated, state-legislated, comprehensive insurance program that requires employers to fund medical expenses, lost wages and other costs resulting from work-related injuries and illnesses. Workers' compensation benefits and arrangements vary extensively on a state-by-state basis and are often highly complex. State statutes and court decisions control many aspects of the compensation process, including claims handling, impairment or disability evaluation, dispute settlement, benefit amount guidelines and cost-control strategies.

Workers' compensation plans generally require employers to fund all of an employee's costs of medical treatment and a significant portion of lost wages, legal fees and other associated costs. In certain jurisdictions, provision of vocational rehabilitation is also mandatory. Typically, work-related injuries are broadly defined, and injured or ill employees are entitled to extensive benefits. Employers generally are required to provide

first-dollar coverage with no co-payment or deductible due from the injured or ill employee for medical coverage for employees, employers generally are not subject to litigation by employees for benefits in excess of those provided by the relevant state statute(s). In most states, the extensive benefits coverage (for both medical costs and lost wages) is provided to employees through the employer's purchase of commercial insurance from private insurance companies, participation in state-run insurance funds or self-insurance.

Healthcare provider reimbursement methods vary on a state-by-state basis. A majority of states (forty as of March 1, 2004) have adopted fee schedules pursuant to which all healthcare providers are uniformly reimbursed. The fee schedules are set individually by each state and generally prescribe the maximum amounts that may be reimbursed for a designated procedure. In states without fee schedules, healthcare providers generally are reimbursed based on usual, customary and reasonable fees charged in the particular state in which services are provided.

Many states do not permit employers to restrict a claimant's choice of provider, making it more difficult for employers to utilize managed care approaches such as HMOs and Preferred Provider Organizations ("PPOs"). However, in many other states, employers have the right to direct employees to a specific primary healthcare provider during the onset of a workers' compensation case, subject to the right of the employee to change physicians after a specific period. In addition, workers' compensation programs vary from state to state, making it difficult for payors and multi-state employers to adopt uniform policies to administer, manage, and control the costs of benefits. As a result, the Company believes that managing the cost of workers' compensation requires approaches which are tailored to the specified regulatory environment(s) in which the employer is operating. Because workers' compensation benefits are mandated by law and are subject to extensive regulation, the Company believes that payors and employers do not have the same flexibility to alter benefits as they might have with other health benefits programs.

Managed care techniques are intended to control the cost of healthcare services and to measure the performance of providers through intervention and ongoing review of services proposed and those actually provided. Managed care techniques were originally developed to stem the rising costs of group medical care. Historically, employers were slow to apply managed care techniques to workers' compensation costs primarily because the aggregate costs are relatively small compared to costs associated with group health benefits and because state-by-state regulations related to workers' compensation are far more complex than those related to group health. However, in recent years, the Company believes that employers and insurance carriers have been increasing their focus on applying managed care techniques to control their workers' compensation costs.

An increasing number of states have adopted legislation encouraging the use of workers' compensation managed care organizations ("MCOs") in an effort to allow employers to control their worker's compensation costs. MCO laws generally provide employers an opportunity to channel injured employees into provider networks. In certain states, MCO laws require licensed MCOs to offer certain specified services, such as utilization management, case management, peer review and provider bill review. The Company believes that most of the MCO laws adopted to date establish a framework within which a company such as CorVel can provide its customers a full range of managed care services for greater cost control.

Business Strategy

The Company believes that payors and employers impacted by the escalating medical costs of healthcare and workers' compensation will increasingly require services and programs to manage such costs. CorVel has developed a continuum of services that responds to this requirement, and intends to further expand its cost containment solutions such as its Patient Management and Network Solutions. The Company's business strategy is to offer a range of services through a national network of branch offices, supported by information management systems to respond to such needs on both a local and national level.

Breadth of Service

A key element of the Company's strategy is to offer a range of services, including claims management, bill review, PPOs and directed care services, which assist insurance carriers, TPAs and self-administered

employers in managing the cost of healthcare and workers' compensation and monitoring the quality of care provided. The Company plans to expand its range of services to respond to the needs of its customers.

National Branch Office Network

An integral part of the Company's strategy is to offer services at the local or regional level where healthcare workers' compensation claims are administered. Each office has access to centralized services and software developed at the Company's corporate offices, which the Company believes enables each office to respond to the particular regulatory environment in which it operates. The Company generally adds branch offices by identifying target markets, generally geographically contiguous to an existing market, where it believes it can successfully introduce one or more of its services. The Company may also establish new offices in response to the needs of national customers. In addition to expanding the number of branch office locations, the Company expects to add existing services as well as new services to its branch offices.

Information Management Capabilities

The Company's strategy also includes improving existing and developing new proprietary software and expanding its wide area network capable of supporting the review and management of medical information on the Internet. Claims and patient data can be entered from field locations, processed by the Company and made available over the Internet for consolidated reporting or for automated access by customers from their own computer systems. The Company expects to derive additional cost savings through the use of advanced rules engines and artificial intelligence technology.

Business

The Company offers services in two general categories, Network Solutions and Patient Management services, to assist its customers in managing the increasing medical costs of workers' compensation, group health and auto insurance, and monitoring the quality of care provided to claimants.

Network Solutions

The Company's Network Solutions services are designed to reduce the price paid by its customers for medical services rendered in workers' compensation cases. The Network Solutions offered by the Company include automated medical fee auditing, preferred provider services, and retrospective utilization review.

Proprietary Bill Review System

Many states have adopted fee schedules, which regulate the maximum allowable fees payable under workers' compensation for procedures performed by a variety of health treatment providers. Such schedules may also include fees for hospital treatment. The purpose of a fee schedule is to standardize the billing process by using uniform procedure descriptions and to set maximum reimbursement levels for each covered service.

Certain other states permit payors to pay workers' compensation medical costs limited to usual and customary charges for the relevant community. The Company provides automated medical fee auditing to assist its customers in verifying that the fees charged by workers' compensation healthcare providers comply with state fee schedules, or are consistent with usual and customary charges.

The Company offers its fee schedule auditing through an automated medical bill review service called MedCheck, which combines automated data reporting and transmission capabilities. MedCheck consists of an online computer-based information system comprised of a proprietary software program which stores and accesses state-mandated fee schedules and usual and customary charge information.

MedCheck is also being utilized for the review of medical charges under certain non-workers' compensation insurance coverages. The MedCheck service provides the following capabilities:

- Checking for provider charges which exceed charges allowable under fee schedules or usual and customary charges, in accordance with the requirements of the relevant jurisdiction

- Repricing provider bills to contractual PPO reimbursement levels
- Checking for duplicate billing
- Checking for billed services or procedures that are excessive, unnecessary or unrelated to treating the particular medical problem
- Checking for "unbundled" billings where the medical services performed are billed in components, resulting in higher total charges than would be the case if the services were billed in the aggregate
- Engaging in on-site processing of claims
- Sending claims data directly to carriers' databases, thereby reducing costs due to repetitive or erroneous data entry
- PPO management
- Internet-based reporting tools
- Pharmacy review

These systems can be accessed by insurers through the Company's wide area network ("WAN") as well as through its website and virtual private networks ("VPNs"). When installed on-site at an insurer, the MedCheck suite can accept electronic data interfaces ("EDIs") from CorVel and other sources. This system automates the reimbursement of providers, allows for the application of all MedCheck fees to the individual claim file and eliminates the need for manual redundant data entry of MedCheck results by the carriers' claims personnel. In addition, MedCheck can send its own files on to the mainframe claims administration systems of major insurers and other payors. The system is designed for easy access by claims adjusters and includes functionality for such part-time users within the claims payment environment.

MedCheck includes an artificial intelligence ("AI") module, called First Review, which allows insurers to incorporate the latest in software intelligence as the software uses rules to determine greater bill review savings. An important element of the Company's business strategy is to introduce MedCheck to additional existing branch offices and increase its use by current customers. The Company plans to continue to invest in the expansion of its MedCheck medical review software to better serve the claims processing needs of customers through automated access.

CorVel customers can utilize MedCheck's service bureau capabilities to outsource their bill review processing needs, process varying portions of their workload from their own sites, or utilize MedCheck on an application service provider ("ASP") basis. Through the ASP, the claims administration organization can access the Med Check software over the Internet and process all, or a portion of their claims, themselves. ASP processing provides payors the MedCheck capabilities without the need for the payors to invest heavily in computer systems, software support, and maintenance or the administration of the many information databases critical to proper medical reimbursement adjudication.

Preferred Provider Organization

Preferred Provider Organizations (PPOs) are groups of hospitals, physicians and other healthcare providers that offer services at pre-negotiated rates to employee groups. The Company believes that PPO networks offer the employer an additional means of managing workers' compensation costs by reducing the per-unit price of medical services provided to employees. The Company launched its CorCare network in 1992 and provides its customers with access to its PPO network, including more than 500,000 healthcare providers nationwide.

PPO providers are selected based on criteria such as quality, range of services, price and location, and each one is evaluated and credentialed, then re-credentialed bi-annually by the Company. Throughout this evaluation process, the CorCare networks are able to provide hospital, physician and special ancillary medical discounts while maintaining quality care.

CorVel is committed to a long-term strategy of network development, providing comprehensive networks to our customers, and customization of networks to meet the specific needs of our customers. The Company believes that a combination of the National PPO Director's strength and presence and the PPO Developer's commitment and community involvement enables CorVel to build, support and strengthen its PPO in size, quality, depth of discounts, and commitment to service.

Over 80% of the providers in our network are directly contracted. CorVel does maintain some leased network access agreements only to the extent to which they provide broader network access capabilities, such as size, demographics and discounts, and to the extent that they enable CorVel to provide prompt response to network expansion requests while maintaining quality assurance controls.

In total, CorVel has more than 220 national, regional and local personnel supporting the CorCare network. This number includes our National PPO Director, National PPO Contracting Manager and contracting staff, in addition to 70 locally based PPO developers who are responsible for local recruitment, contract negotiations, credentialing and re-credentialing of providers, and working with customers to develop customer specific provider networks. Each Bill Review Unit has Provider Relations support staff to address provider grievances and other billing issues.

Bills submitted from preferred providers are identified through the MedCheck bill review process, and the submitted charges are then audited against the PPO schedule and against any applicable fee schedule or usual and customary charges. The fee approved for payment is the lower of the submitted charges or the lowest allowable fee identified. Some of the features of the Company's PPO network services include: national networks for all coverages, board certified physicians, automated provider credentialing, patient channeling, online provider look-up and printable directories.

CorVel has the capability to provide checkwriting services for its customers. The provider payment check can be added to the bill analysis to produce one combined document, which is mailed to the provider.

The Company offers online provider look-up on its website where users can locate providers in their area, see a map, get door to door driving directions or print a directory.

Retrospective Utilization Review

The Company offers a full line of retrospective utilization services for all medical bills including PPO management, medical bill repricing, line-item bill review, professional nurse review, DRG validation and fee negotiation. The service, named MedCheck Select, is designed to maximize savings opportunities and increase efficiencies for customers.

CorVel offers cost containment by examining medical bills to verify that payors are only charged for services actually delivered and that charges reflect current billing levels for comparable service.

CorVel uses a combination of industry standard usual and customary databases, as well as a proprietary nationwide database of usual and customary charges for inpatient care. The inpatient database provides usual and customary charges for the detailed charges, which are specified on the itemized hospital bill. MedCheck Select employs experienced fee negotiators who work with providers to reach agreement on the proper level of reimbursement.

MedCheck Select service:

- Assures that billed charges are usual and customary
- Confirms services were medically necessary
- Reduces claim costs through negotiated agreements
- Substantiates, by report, charges over usual and customary
- Supports the payor and patient in all appeals
- Reviews Out-of-Network bills

- Provides a proprietary hospital usual and customary database
- Reviews professional nurses
- Provides expert fee negotiations
- Validates diagnostic related groups
- Is HIPAA and AB1455 compliant

Directed Care Networks

CorVel has expanded its preferred provider organization with a directed care network. CorCare Select, CorVel's directed care service line, offers an automated service ordering and status management system through CorVel's Care^{MC} website. Our network service offers timely appointments and preferred pricing. Orders are fulfilled using local, preferred providers and billing and reimbursement for each transaction is automatically processed. Services also include web-based request for service, a call center, and online reporting.

CorCare Select services include:

- Independent Medical Examinations
- Diagnostic Imaging
- Durable Medical Equipment
- Physical Therapy
- Chiropractic

Patient Management Services

In addition to its network solutions, the Company offers CorCase, a range of patient management services, which involve working on a one-on-one basis with injured employees and their various healthcare professionals, employers and insurance company claims professionals. Patient management services are designed to monitor the medical necessity and appropriateness of healthcare services provided to workers' compensation claimants and to expedite their return to work. The Company offers these services on a stand-alone basis, or as an integrated component of its medical cost containment services.

CorCase is CorVel's line of case management solutions for the managed care industry. The CorCase suite of services includes: first notice of loss, early intervention, utilization management, telephonic case management, on-site case management, peer review, vocational rehabilitation, Medicare set asides and life care planning.

CorCase utilizes CorVel's proprietary Advocacy software to help case managers determine available indemnity payments from the employer and coordinate case management information and issues. Protocols regarding length of disability are incorporated to guide the management of cases. Management and operations reports, electronic data interchange and billing are additional features of the software.

Medical Case Management

The Company offers medical case management services where the injury is catastrophic or complex in nature, or where prolonged recovery is anticipated. The medical management components of CorVel's program focuses on medical intervention, management and appropriateness. In these cases, the Company's case managers confer with the attending physician, other providers, the patient and the patient's family to identify the appropriate rehabilitative treatment and most cost-effective healthcare alternatives. The program is geared towards offering the injured party prompt access to appropriate medical providers who will provide quality cost-effective medical care. Case managers may coordinate the services or care required and may arrange for special pricing of the required services.

Telephonic Case Management

Telephonic case management is designed to facilitate and promote patient care and patient progression through the healthcare system. The case manager, through telephonic contact with the patient and/or family, facilitates communication between the patient, insurer, and healthcare providers in order to accelerate return to work.

Vocational Rehabilitation

In certain states, vocational rehabilitation is a legislated benefit of workers' compensation, which assists the employee's return to former employment or another job function with similar economic value. The Company offers vocational services to reduce workers' compensation costs and expedite the injured employee's return to work.

CorVel offers vocational services to evaluate the claimant's education, training, and experience. Vocational services include work capacity assessments, job analysis, transferable skill analysis, job modification, vocational testing, job placement assistance, labor market surveys and retraining. By working with the employer, the Company's case managers can provide job modification or light-duty alternatives until the physician lifts the claimant's physical restrictions. In addition, CorVel can evaluate partial payment claims if the claimant returns to work in a new position, working for less than their pre-injury wage.

Early Intervention

The Company believes that the earlier it becomes involved in an episode of care, the greater the impact on the healthcare outcome. The Company's early intervention program begins a series of steps that are designed to promote an employee's timely return-to-work including immediate telephonic assessment to ensure that an appropriate course of treatment is established and adhered to through the entire episode of care. CorVel's early intervention program features: automated, immediate notification, immediate patient assessment, clinical protocols and guidelines, channeling to preferred providers, private labeling options, and telephonic case management.

Utilization Management

Utilization Management programs preview proposed ambulatory care to determine: appropriateness, frequency, duration and setting. These programs utilizing experienced RN's, proprietary medical treatment protocols, and expert systems technology in an effort to avoid unnecessary treatments and associated costs. Processes in Utilization Management include: review injury, diagnosis, and treatment plan; contact and negotiate provider's treatment requirements; certify appropriateness of treatment parameters and/or additional treatment requests; and respond to provider requests for additional treatment.

Precertification of Hospitalization

The pre-admission certification program verifies the medical necessity of proposed hospital admissions, and determines the appropriate length of stay. The CorVel staff of nurses and reviewers, assisted by an automated medical rules/protocols system and backed up by physician consultants, individually evaluates every hospital admissions request. Precertification objectives include the following: determine appropriateness of proposed or emergent hospitalization; determine the medical necessity for hospital admission/inpatient care; explore alternatives to inpatient treatment; if inpatient care is required, determine the appropriate length of stay and monitor the patient's condition throughout the hospitalization to prevent unnecessary inpatient days; channel the patient to a CorVel PPO provider/facility; and develop and implement a timely discharge plan.

Inpatient Utilization Review

The Company offers precertification and concurrent utilization review services. The Company's precertification service is designed to be utilized prior to the injured employee's admission to the hospital. Upon

notification by a claims manager or employer, a Company nurse reviews the appropriateness of the proposed plan of care, the need for inpatient hospitalization, and the appropriate length of stay. Under the Company's concurrent review service the nurse reviewers monitor the medical necessity and appropriateness of the patient's continued hospitalization through regular contact with the hospital and the patient's physician and may identify cases that lend themselves to alternate treatment settings or home care.

Care^{MC}

The Company continues to invest in and develop its business-to-business Care^{MC} website. Care^{MC} connects employers, claims professionals, providers and case managers, and is designed to accelerate the resolution of claims and reduce costs. Care^{MC} integrates all of the claims management processes involved in the life of a claim, and extends the automated processing of incident reporting to other components of claims management. Care^{MC} is intended to serve the healthcare and claims needs of insurers and employers managing employee disability insurance losses. The Care^{MC} website provides direct access to CorVel's managed care services and is also designed to function as an ASP through which other managed care providers can supply their services to major employers and insurers nationwide.

The Care^{MC} website facilitates healthcare transaction processing. Information gathered in Care^{MC} is immediately consolidated and available to payors, claims professionals, case managers and treating physicians. Using artificial intelligence techniques, the website provides situation alerts and event triggers, to facilitate prompt and effective decisions. Users of Care^{MC} can quickly see where event outliers are occurring within the claims management process. If costs exceed pre-determined thresholds or activities fall outside expected timelines, decision-makers can be quickly notified. Large amounts of information are consolidated and summarized to help customers focus on the critical issues.

Care^{MC} offers a suite of online services and solutions that unite multiple claims management and managed care professionals in real-time, and on a single website, to create a seamless, unified process for claims. This suite of solutions for managed care professionals includes:

Referral Basket: The Referral Basket provides users access to submit first notice of loss and various requests for service. The referral basket is a central access point to contact multiple managed care professionals from multiple resources, facilitating instant access to claims information. Referrals are automatically routed to the preferred managed care provider and confirmed as received in real-time.

Claims Center: The Claims Center helps claims professionals organize and prioritize their claims. Claims professionals can access comprehensive, detailed information on open, closed or pending claims from multiple managed care providers. Through the Care^{MC} Claims Center, the claims professional can interact with multiple managed care providers in real time, accessing real time claims updates or request service on a claim.

Bill Review: With Care^{MC} Bill Review, claims professionals can review and approve medical bills from their desktop. Users can access bill review status instantly, review scanned bills, and authorize payments online based on fee schedules and PPO agreements. Additionally, the claims professionals can reimburse providers for services directly after the bill has been approved for payment in real time.

Reporting Center: The Reporting Center collects a myriad of critical details from multiple sources, then organizes and delivers that information in real time. Care^{MC} helps claims professionals by sorting, simplifying and formatting comprehensive case data. Reports can be tailored to highlight individual critical cases or summarized to highlight priority trends. Through the Care^{MC} Reporting Center, claims professionals can view timely status reports and cost updates, flag priority issues, tailor reports to highlight urgent cases or summarize important trends, and perform cost and savings analyses.

Customers and Marketing

The Company's customers primarily are workers' compensation insurers and, to a lesser extent, TPAs and self-administered employers. Many claims management decisions in workers' compensation are the responsibility of the local claims office of national or regional insurers. The Company's national branch office network

has been established to enable the Company to market and offer its services at both a local and national account level. The Company is placing increasing emphasis on national account marketing. The marketing activities of the Company are conducted by account executives located in key geographic areas. No single customer of the Company represented more than 10% of revenues in fiscal 2002, 2003 or 2004.

Competition and Market Conditions

The healthcare cost containment industry is highly fragmented and competitive, and is subject to shifting customer requirements, frequent introductions of new products and services, increased marketing activities of other industry participants, and legislative reforms. The Company expects intensity of competition to increase in the future as existing competitors continue to develop their products and services and as new companies enter the Company's market. The Company's primary competitors in the workers' compensation market include some large insurance carriers which offer one or more services similar to those offered by the Company, HMOs and numerous independent companies, typically on a local or regional basis. The Company also competes with national and local firms specializing in utilization review and with major insurance carriers and TPAs which have implemented their own internal utilization review services. Many of the Company's competitors are significantly larger and have greater financial and marketing resources than the Company. Moreover, the Company's customers may establish the in-house capability of performing services offered by the Company. If the Company is unable to compete effectively, it will be difficult for the Company to add and retain customers, and the Company's business, financial condition and results of operations will be seriously harmed.

Legislative reforms in some states permit employers to designate health plans such as HMOs and PPOs to cover workers' compensation claimants. Because many health plans have the capacity to manage healthcare for workers' compensation claimants, such legislation may intensify competition in the market served by the Company.

The Company believes that declines in workers' compensation costs in these states are due principally to intensified efforts by payors to manage and control claim costs, to improved risk management by employers and to legislative reforms. If declines in workers' compensation costs occur in many states and persist over the long-term, they may have an adverse impact on the Company's business, financial condition and results of operations.

The Company believes the principal factors that generally determine a company's competitive advantage in the Company's market include the following: specialization in workers' compensation, breadth of services, ability to offer local services on a nationwide basis, information management systems and independence from insurance carriers. There can be no assurance that the Company will be successful in all or any of these areas that the Company believes contribute to competitive advantage, or that the Company will be able to compete successfully against current or potential competitors, or that competition will not have a material adverse effect on the Company's business, financial condition and results of operations.

Government Regulation

General

Managed healthcare programs for workers' compensation are subject to various laws and regulations. Both the nature and degree of applicable government regulation vary greatly depending upon the specific activities involved. Generally, parties that actually provide or arrange for the provision of healthcare services, assume financial risk related to the provision of those services, or undertake direct responsibility for making payment or payment decisions for those services, are subject to a number of complex regulatory schemes that govern many aspects of their conduct and operations.

In contrast, the management and information services provided by the Company to its customers typically have not been the subject of regulation by the federal government or the states. Since the managed healthcare field is a rapidly expanding and changing industry and the cost of providing healthcare continues to

increase, it is possible that the applicable state and federal regulatory frameworks will expand to have a greater impact upon the conduct and operation of the Company's business.

Under the current workers' compensation system, employer insurance or self-funded coverage is governed by individual laws in each of the 50 states and by certain federal laws. The management and information services that make up the Company's managed care program serve markets that have developed largely in response to needs of insurers, employers and large TPAs, and generally have not been mandated by legislation or other government action. On the other hand, the vocational rehabilitation case management marketplace within the workers' compensation system has been dependent upon the laws and regulations within those states that require the availability of specified rehabilitation services for injured workers. Similarly, the Company's fee schedule auditing services address market needs created by certain states' enactment of maximum permissible fee schedules for workers' compensation services. Changes in individual state regulation of workers' compensation may create a greater or lesser demand for some or all of the Company's services, or require the Company to develop new or modified services in order to meet the needs of the marketplace and compete effectively in that marketplace.

Health Insurance Portability and Accountability Act of 1996

The Health Insurance Portability and Accountability Act of 1996, or HIPAA, requires the adoption of standards for the exchange of health information in an effort to encourage overall administrative simplification and to enhance the effectiveness and efficiency of the healthcare industry. Pursuant to HIPAA, the Secretary of the Department of Health and Human Services has issued final rules concerning the privacy and security of health information, the establishment of standard transactions and code sets. The HIPAA requirements only apply to covered entities, which include health plans, healthcare clearinghouses, and healthcare providers that transmit any health information in electronic form. The Company's network solutions services may be subject to HIPAA obligations through business associate agreements with our customers. We are also indirectly regulated by HIPAA as a plan sponsor of a healthcare benefit plan for our own employees.

Of the HIPAA requirements, the privacy standards and the security standards have the most significant impact on our business operations. The privacy standards require covered entities to implement certain procedures to govern the use and disclosure of protected health information and to safeguard such information from inappropriate access, use or disclosure. Protected health information includes individually identifiable health information, such as an individual's medical records, transmitted or maintained in any format, including paper and electronic records. The privacy standards establish the different levels of individual permission that are required before a covered entity may use or disclose an individual's protected health information, and establish new rights for the individual with respect to his or her protected health information.

The security standards are designed to protect health information against reasonably anticipated threats or hazards to the security or integrity of the information, and to protect the information against unauthorized use or disclosure. The security standards establish a national standard for protecting the security and integrity of medical records when they are kept in electronic form. Compliance with the security standards is required by April 21, 2005.

Medical Cost Containment Legislation

Historically, governmental strategies to contain medical costs in the workers' compensation field have been generally limited to legislation on a state-by-state basis. For example, many states have implemented fee schedules that list maximum reimbursement levels for healthcare procedures. In certain states that have not authorized the use of a fee schedule, the Company adjusts bills to the usual and customary levels authorized by the payor. Opportunities for the Company's services could increase if more states legislate additional cost containment strategies. Conversely, the Company would be adversely affected if states elect to reduce the extent of medical cost containment strategies available to insurance carriers and other payors, or adopt other strategies for cost containment that would not support a demand for the Company's services.

Healthcare Reform

There has been considerable discussion of healthcare reform at both the federal level and in numerous state legislatures in recent years. Due to uncertainties regarding the ultimate features of reform initiatives and the timing of their enactment, the Company cannot predict which, if any, reforms will be adopted, when they may be adopted, or what impact they may have on the Company.

Vocational Rehabilitation Legislation

During the early 1970s, the case management marketplace within workers' compensation was dominated by the provision of medical management services. Such services were purchased at the option of insurance carriers with little or no support from legislative efforts within any of the states. By the mid-1970s, it became popular for states to legislate either supportive programs for vocational rehabilitation or, in some cases, mandatory vocational rehabilitation statutes.

Shareholder Rights Plan

During fiscal 1997, the Company's Board of Directors approved the adoption of a Shareholder Rights Plan. The Shareholder Rights Plan provides for a dividend distribution to CorVel stockholders of one preferred stock purchase right for each outstanding share of CorVel's common stock. In April, 2002, the Board of Directors of CorVel approved an amendment to the Company's existing stockholder rights agreement to extend the expiration date of the rights to February 10, 2012, increase the initial exercise price of each right to \$118 and enable Fidelity Management & Research Company and its affiliates to purchase up to 18% of the shares of common stock of the Company without triggering the stockholder rights. The limitations under the stockholder rights agreement remain in effect for all other stockholders of the Company. The stockholder rights agreement was originally adopted and approved in 1997. The rights are designed to assure that all stockholders receive fair and equal treatment in the event of any proposed takeover of the Company and to encourage a potential acquirer to negotiate with the Board of Directors prior to attempting a takeover. The rights have an exercise price of \$118 per right, subject to subsequent adjustment. The rights trade with the Company's common stock, and will not be exercisable until the occurrence of certain takeover-related events.

Generally, the Shareholder Rights Plan provides that if a person or group acquires 15% or more of the Company's common stock without the approval of the Board, subject to certain exception, the holders of the rights, other than the acquiring person or group, would, under certain circumstances, have the right to purchase additional shares of the Company's common stock having a market value equal to two times the then-current exercise price of the right.

In addition, if the Company is thereafter merged into another entity, or if 50% or more of the Company's consolidated assets or earning power are sold, then the right will entitle its holder to buy common shares of the acquiring entity having a market value equal to two times the then-current exercise price of the right. The Company's Board of Directors may exchange or redeem the rights under certain conditions.

Employees

As of March 31, 2004, CorVel had 3,215 employees, including nurses, therapists, counselors and other employees. No employees are represented by any collective bargaining unit. Management believes the Company's relationship with its employees to be good.

Available Information

Copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and other filings made with the Securities and Exchange Commission such as reports pursuant to Section 16 of the Securities Exchange Act of 1934, are available free of charge through our website (<http://www.corvel.com>, under the Investor Relations section) as soon as reasonably practicable after such reports are electronically filed with, or furnish it to, the Securities and Exchange Commission. The

inclusion of our web site address in this report does not include or incorporate by reference into this report any information on our web site.

Risk Factors

Past financial performance is not necessarily a reliable indicator of future performance, and investors in the Company's common stock should not use historical performance to anticipate results or future period trends. Investing in the Company's common stock involves a high degree of risk. Investors should consider carefully the following risk factors, as well as the other information in this report and the Company's other filings with the Securities and Exchange Commission, including the Company's consolidated financial statements and the related notes, before deciding whether to invest or maintain an investment in shares of the Company's common stock. If any of the following risks actually occurs, the Company's business, financial condition and results of operations would suffer. In this case, the trading price of the Company's common stock would likely decline. The risks described below are not the only ones the Company faces. Additional risks that the Company currently does not know about or that the Company currently believes to be immaterial also may impair the Company's business operations.

Changes in government regulations could increase the Company's cost of operations and/or reduce the demand for the Company's services.

Many states, including a number of those in which the Company transacts business, have licensing and other regulatory requirements applicable to the Company's business. Approximately half of the states have enacted laws that require licensing of businesses which provide medical review services such as the Company. Some of these laws apply to medical review of care covered by workers' compensation. These laws typically establish minimum standards for qualifications of personnel, confidentiality, internal quality control and dispute resolution procedures. These regulatory programs may result in increased costs of operation for the Company, which may have an adverse impact upon the Company's ability to compete with other available alternatives for healthcare cost control. In addition, new laws regulating the operation of managed care provider networks have been adopted by a number of states. These laws may apply to managed care provider networks having contracts with the Company or to provider networks which the Company may organize. To the extent the Company is governed by these regulations, it may be subject to additional licensing requirements, financial and operational oversight and procedural standards for beneficiaries and providers.

Regulation in the healthcare and workers' compensation fields is constantly evolving. The Company is unable to predict what additional government initiatives, if any, affecting its business may be promulgated in the future. The Company's business may be adversely affected by failure to comply with existing laws and regulations, failure to obtain necessary licenses and government approvals or failure to adapt to new or modified regulatory requirements. Proposals for healthcare legislative reforms are regularly considered at the federal and state levels. To the extent that such proposals affect workers' compensation, such proposals may adversely affect the Company's business, financial condition and results of operations.

In addition, changes in workers' compensation, auto and managed health care laws or regulations may reduce demand for the Company's services, require the Company to develop new or modified services to meet the demands of the marketplace or reduce the fees that the Company may charge for its services. One proposal which has been considered by Congress and certain state legislatures is 24-hour health coverage, in which the coverage of traditional employer-sponsored health plans is combined with workers' compensation coverage to provide a single insurance plan for work-related and non-work-related health problems. Incorporating workers' compensation coverage into conventional health plans may adversely affect the market for the Company's services because some employers would purchase 24 hour coverage from group health plans which could reduce the demand for CorVel's workers compensation customers.

The Company's quarterly sequential revenue growth may not continue to increase in the future. As a result, the Company may fail to meet or exceed the expectations of investors or securities analysts which could cause the Company's stock price to decline.

The Company's quarterly sequential revenue growth may not continue to increase in the future as a result of a variety of factors, many of which are outside of the Company's control. If the Company's quarterly sequential revenue growth falls below the expectations of investors or securities analysts, the price of the Company's common stock could decline substantially. Fluctuations or declines in quarterly sequential revenue growth may be due to a number of factors, including, but not limited to, those listed below and identified throughout this "Risk Factors" section the decline in the manufacturing employment, the decline in workers' compensation claims, the considerable price competition given the flat-to-declining market, the increase in competition, and the changes and the potential changes in state workers' compensation and auto managed care laws which can reduce demand for the Company's services. These factors create an environment where revenue and margin growth is more difficult to attain and where revenue growth is less certain than historically experienced. Additionally, the Company's technology and preferred provider network face competition from companies that have more resources available to them than the Company does. Also, some customers may handle their managed care services in-house and may reduce the amount of services which are outsourced to managed care companies such as CorVel Corporation.

These factors could cause the market price of the Company's Common Stock to fluctuate substantially. Specifically, the year-to-year percentage growth in operating results for the Company's four most recently completed fiscal years was lower than the growth rates historically experienced by the Company. The Company's slower growth rate in those fiscal years was partially attributable to a reduction in the growth rate of healthcare expenditures nationally, contributing to a reduction in the growth of claims processed by the Company. There can be no assurance that the Company's growth rate in the future, if any will be at or near historical levels.

In addition, the stock market has in the past experienced price and volume fluctuations that have particularly affected companies in the healthcare and managed care markets resulting in changes in the market price of the stock of many companies which may not have been directly related to the operating performance of those companies.

Due to the foregoing factors, and the other risks discussed in this report, investors should not rely on quarter-to-quarter comparisons of the Company's results of operations as an indication of its future performance.

Exposure to possible litigation and legal liability may adversely affect the Company's business, financial condition and results of operations.

The Company, through its utilization management services, makes recommendations concerning the appropriateness of providers' medical treatment plans of patients throughout the country, and as a result, could be exposed to claims for adverse medical consequences. The Company does not grant or deny claims for payment of benefits and the Company does not believe that it engages in the practice of medicine or the delivery of medical services. There can be no assurance, however, that the Company will not be subject to claims or litigation related to the authorization or denial of claims for payment of benefits or allegations that the Company engages in the practice of medicine or the delivery of medical services.

In addition, there can be no assurance that the Company will not be subject to other litigation that may adversely affect the Company's business, financial condition or results of operations, including but not limited to being joined in litigation brought against the Company's customers in the managed care industry. The Company maintains professional liability insurance and such other coverages as the Company believes are reasonable in light of the Company's experience to date. There can be no assurance; however, that such insurance will be sufficient or available in the future at reasonable cost to protect the Company from liability which might adversely affect the Company's business, financial condition or results of operations.

The Company's failure to compete successfully could make it difficult for the Company to add and retain customers and could reduce or impede the growth of the Company's business.

The Company faces competition from PPOs, TPAs and other managed healthcare companies. The Company believes that as managed care techniques continue to gain acceptance in the workers' compensation marketplace, CorVel's competitors will increasingly consist of nationally focused workers' compensation managed care service companies, insurance companies, HMOs and other significant providers of managed care products. Legislative reforms in some states permit employers to designate health plans such as HMOs and PPOs to cover workers' compensation claimants. Because many health plans have the ability to manage medical costs for workers' compensation claimants, such legislation may intensify competition in the markets served by the Company. Many of the Company's current and potential competitors are significantly larger and have greater financial and marketing resources than those of the Company, and there can be no assurance that the Company will continue to maintain its existing clients or its past level of operating performance or be successful with any new products or in any new geographical markets it may enter.

Healthcare providers are becoming increasingly resistant to the application of certain healthcare cost containment techniques, which could cause the Company's revenue to decrease.

Healthcare providers have become more active in their efforts to minimize the use of certain cost containment techniques and are engaging in litigation to avoid application of certain cost containment practices. Recent litigation between healthcare providers and insurers has challenged certain insurers' claims adjudication and reimbursement decisions. Although these lawsuits do not directly involve us or any services that we provide, these cases could affect the use by insurers of certain cost containment services that we provide, and could result in a decline in revenue from our cost containment line of business.

A change in market dynamics may harm the Company's results of operations.

Within the past few years, several states have experienced a decline in the number of workers' compensation claims and the average cost per claim which have been reflected in workers' compensation insurance premium rate reductions in those states. The Company believes that declines in workers' compensation costs in these states are due principally to intensified efforts by payors to manage and control claim costs, to improved risk management by employers and to legislative reforms. If declines in workers' compensation costs occur in many states and persist over the long-term, they may have an adverse impact on the Company's business, financial condition and results of operations.

The Company provides an outsource service to payors of workers compensation and auto healthcare benefits. These payors include insurance companies, TPA's, municipalities, state funds, and self-insured, self-administered employers. If these payors reduce the amount of work they outsource, the Company's results of operations could be adversely affected.

If the average annual growth in nationwide employment does not offset declines in the frequency of workplace injuries and illnesses, then the size of our market may decline and adversely affect our ability to grow.

The rate of injuries that occur in the workplace has decreased over time. Although the overall number of people employed in the workplace has generally increased over time, this increase has only partially offset the declining rate of injuries and illnesses. Our business model is based, in part, on our ability to expand our relative share of the market for the treatment and review of claims for workplace injuries and illnesses. If nationwide employment does not increase or experiences periods of decline, or if workplace injuries and illnesses continue to decline at a greater rate than the increase in total employment, our ability to expand our revenue and earnings could be unfavorably impacted.

If the utilization by healthcare payors of early intervention services continues to increase, the revenue from our later stage network and healthcare management services could be negatively affected.

The performance of early intervention services, including injury occupational healthcare, first notice of loss, and telephonic case management services, often result in a decrease in the average length of, and the total costs associated with, a healthcare claim. By successfully intervening at an early stage in a claim, the need for

additional cost containment services for that claim often can be reduced or even eliminated. As healthcare payors continue to increase their utilization of early intervention services, the revenue from our later stage network and healthcare management services may decrease.

The Company faces competition for staffing, which may increase its labor costs and reduce profitability.

The Company competes with other health-care providers in recruiting qualified management and staff personnel for the day-to-day operations of its business, including nurses and other case management professionals. In some markets, the scarcity of nurses and other medical support personnel has become a significant operating issue to health-care providers. This shortage may require the Company to enhance wages to recruit and retain qualified nurses and other health-care professionals. The failure of the Company to recruit and retain qualified management, nurses and other health-care professionals, or to control labor costs could have a material adverse effect on profitability.

The failure to attract and retain qualified or key personnel may prevent the Company from effectively developing, marketing, selling, integrating and supporting its services.

The Company is dependent to a substantial extent upon the continuing efforts and abilities of certain key management personnel. In addition, the Company faces competition for experienced employees with professional expertise in the workers' compensation managed care area. The loss of, or the inability to attract, qualified employees, especially V. Gordon Clemons, Chairman and President, could have a material unfavorable effect on the Company's business and results of operations.

If the Company fails to manage its growth effectively, it may be unable to execute its business plan, maintain high levels of service or adequately address competitive challenges.

The Company's strategy is to continue its internal growth and, as strategic opportunities arise in the workers' compensation managed care industry, to consider acquisitions of, or relationships with, other companies in related lines of business. As a result, the Company is subject to certain growth-related risks, including the risk that it will be unable to retain personnel or acquire other resources necessary to service such growth adequately. Expenses arising from the Company's efforts to increase its market penetration may have a negative impact on operating results. In addition, there can be no assurance that any suitable opportunities for strategic acquisitions or relationships will arise or, if they do arise that the transactions contemplated thereby could be completed. If such a transaction does occur, there can be no assurance that the Company will be able to integrate effectively any acquired business into the Company. In addition, any such transaction would be subject to various risks associated with the acquisition of businesses, including, but not limited to, the following:

- an acquisition may negatively impact the Company's results of operations because it may require incurring large one-time charges, substantial debt or liabilities; it may require the amortization or write down of amounts related to deferred compensation, goodwill and other intangible assets; or it may cause adverse tax consequences, substantial depreciation or deferred compensation charges;
- the Company may encounter difficulties in assimilating and integrating the business, technologies, products, services, personnel or operations of companies that are acquired, particularly if key personnel of the acquired company decide not to work for the Company;
- an acquisition may disrupt ongoing business, divert resources, increase expenses and distract management;
- the acquired businesses, products, services or technologies may not generate sufficient revenue to offset acquisition costs;
- the Company may have to issue equity securities to complete an acquisition, which would dilute stockholders and could adversely affect the market price of the Company's common stock; and
- acquisitions may involve the entry into a geographic or business market in which the Company has little or no prior experience.

There can be no assurance that the Company will be able to identify or consummate any future acquisitions or other strategic relationships on favorable terms, or at all, or that any future acquisition or other strategic relationship will not have an adverse impact on the Company's business or results of operations. If suitable opportunities arise, the Company anticipates that it would finance such transactions, as well as its internal growth, through working capital or, in certain instances, through debt or equity financing. There can be no assurance, however, that such debt or equity financing would be available to the Company on acceptable terms when, and if, suitable strategic opportunities arise.

Our Internet-based services are dependent on the development and maintenance of the Internet infrastructure.

We deploy our Care^{MC} and, to a lesser extent, MedCheck services over the Internet. Our ability to deliver our Internet-based services is dependent on the development and maintenance of the infrastructure of the Internet by third parties. This includes maintenance of a reliable network backbone with the necessary speed, data capacity and security, as well as timely development of complementary products, such as high-speed modems, for providing reliable Internet access and services. The Internet has experienced, and is likely to continue to experience, significant growth in the number of users and the amount of traffic. If the Internet continues to experience increased usage, the Internet infrastructure may be unable to support the demands placed on it. In addition, the performance of the Internet may be harmed by increased usage.

The Internet has experienced a variety of outages and other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of Internet usage, as well as the availability of the Internet to us for delivery of our Internet-based services. In addition, our customers who use our Web-based services depend on Internet service providers, online service providers and other Web site operators for access to our Web site. All of these providers have experienced significant outages in the past and could experience outages, delays and other difficulties in the future due to system failures unrelated to our systems. Any significant interruptions in our services or increases in response time could result in a loss of potential or existing users, and, if sustained or repeated, could reduce the attractiveness of our services.

Demand for our services could be adversely affected if our prospective customers are unable to implement the transaction and security standards required under HIPAA.

For some of our network services, we routinely implement electronic data interfaces ("EDIs") to our customers' locations that enable the exchange of information on a computerized basis. To the extent that our customers do not have sufficient personnel to implement the transactions and security standards required by HIPAA or to work with our information technology personnel in the implementation of our electronic interfaces, the demand for our network services could decline.

An interruption in the Company's ability to access critical data may cause customers to cancel their service and/or may reduce the Company's ability to effectively compete.

Certain aspects of the Company's business are dependent upon its ability to store, retrieve, process and manage data and to maintain and upgrade its data processing capabilities. Interruption of data processing capabilities for any extended length of time, loss of stored data, programming errors or other system failures could cause customers to cancel their service and could have a material adverse effect on the Company's business and results of operations. The Company is currently in the process of installing new company-wide management information software and there can be no assurance that the installation of this new system will proceed according to plan.

In addition, the Company expects that a considerable amount of its future growth will depend on its ability to process and manage claims data more efficiently and to provide more meaningful healthcare information to customers and payors of healthcare. There can be no assurance that the Company's current data processing capabilities will be adequate for its future growth, that it will be able to efficiently upgrade its systems to meet future demands, or that the Company will be able to develop, license or otherwise acquire software to address these market demands as well or as timely as its competitors.

The introduction of software products incorporating new technologies and the emergence of new industry standards could render the Company's existing software products less competitive, obsolete or unmarketable.

There can be no assurance that the Company will be successful in developing and marketing new software products that respond to technological changes or evolving industry standards. If the Company is unable, for technological or other reasons, to develop and introduce new software products cost-effectively in a timely manner in response to changing market conditions or customer requirements, the Company's business, results of operations and financial condition may be adversely affected.

Developing or implementing new or updated software products and services may take longer and cost more than expected. The Company relies on a combination of internal development, strategic relationships, licensing and acquisitions to develop its software products and services. The cost of developing new healthcare information services and technology solutions is inherently difficult to estimate. The Company's development and implementation of proposed software products and services may take longer than originally expected, require more testing than originally anticipated and require the acquisition of additional personnel and other resources. If the Company is unable to develop new or updated software products and services cost-effectively on a timely basis and implement them without significant disruptions to the existing systems and processes of the Company's customers, the Company may lose potential sales and harm its relationships with current or potential customers.

A breach of security may cause the Company's customers to curtail or stop using the Company's services.

The Company relies largely on its own security systems, confidentiality procedures and employee nondisclosure agreements to maintain the privacy and security of its [and its customers'] proprietary information. Accidental or willful security breaches or other unauthorized access by third parties to the Company's information systems, the existence of computer viruses in the Company's data or software and misappropriation of the Company's proprietary information could expose the Company to a risk of information loss, litigation and other possible liabilities which may have a material adverse effect on the Company's business, financial condition and results of operations. If security measures are breached because of third-party action, employee error, malfeasance or otherwise, or if design flaws in the Company's software are exposed and exploited, and, as a result, a third party obtains unauthorized access to any customer data, the Company's relationships with its customers and its reputation will be damaged, the Company's business may suffer and the Company could incur significant liability. Because techniques used to obtain unauthorized access or to sabotage systems change frequently and generally are not recognized until launched against a target, the Company may be unable to anticipate these techniques or to implement adequate preventative measures.

Changes in the accounting treatment of stock options could adversely affect the Company's results of operations.

The Financial Accounting Standards Board has recently announced its tentative decision to require companies to expense employee stock options in accordance with Statement of Financial Accounting Standards ("SFAS") No. 123, *Accounting for Stock-Based Compensation*, for financial reporting purposes, effective in 2005. Such stock option expensing would require the Company to value its employee stock option grants pursuant to a binomial valuation formula, and then amortize that value against the Company's reported earnings over the vesting period in effect for those options. The Company currently accounts for stock-based awards to employees in accordance with Accounting Principles Board ("APB") Opinion No. 25, *Accounting for Stock Issued to Employees*, and has adopted the disclosure-only alternative of SFAS 123. If the Company is required to expense employee stock options in the future, this change in accounting treatment would materially and adversely affect the Company's reported results of operations as the stock-based compensation expense would be charged directly against the Company's reported earnings. For an illustration of the effect of such a change on the Company's recent results of operations, see Note A of Notes to Consolidated Financial Statements. Participation by the Company's employees in the Company's employee stock purchase plan may trigger additional compensation charges if the proposed amendments to SFAS 123 are adopted.

Item 2. Properties.

The Company's principal executive office is located in Irvine, California in approximately 6,600 square feet of leased space. The lease expires in September 2007. The Company leases its branch offices in 49 states, which range in size from 1,000 square feet up to approximately 16,000 square feet. The lease terms for the branch offices range from monthly to seven years. The Company believes that its facilities are adequate for its current needs and that suitable additional space will be available as required.

Item 3. Legal Proceedings.

The Company is involved in litigation arising in the normal course of business. The Company believes that resolution of these matters will not result in any payment that, in the aggregate, would be material to the financial position or financial operations of the Company.

Item 4. Submission of Matters to a Vote of Security Holders.

There were no matters submitted to a vote of stockholders during the quarter ended March 31, 2004.

PART II**Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities****Market Information**

The Company's Common Stock is traded on the NASDAQ National Market under the symbol CRVL. The quarterly high and low sales prices for the Company's Common Stock for fiscal years 2003 and 2004 as reported by NASDAQ are set forth below for the periods indicated:

	<u>High</u>	<u>Low</u>
Fiscal Year Ended March 31, 2003:		
Quarter Ended June 30, 2002:	\$35.87	\$29.50
Quarter Ended September 30, 2002:	34.71	27.70
Quarter Ended December 31, 2002:	36.60	29.09
Quarter Ended March 31, 2003:	36.30	30.30
Fiscal Year Ended March 31, 2004:		
Quarter Ended June 30, 2003:	\$36.14	\$29.86
Quarter Ended September 30, 2003:	38.78	34.20
Quarter Ended December 31, 2003:	38.15	32.63
Quarter Ended March 31, 2004:	40.80	34.02

Holders. As of May 28, 2004, there were 1,142 holders of record of the Company's Common Stock. The Company has never paid any cash dividends on its Common Stock and has no current plans to do so in the foreseeable future.

Dividends. The Company has never paid any cash dividends on its Commons Stock and has no current plans to do so in the foreseeable future. The Company intends to retain future earnings, if any, for use in the Company's business. The payment of any future dividends on its Common Stock will be determined by the Board of Directors in light of conditions then existing, including the Company's earnings, financial condition and requirements, restrictions in financing agreements, business conditions and other factors.

Issuer Purchases of Equity Securities. The following table shows the number of shares repurchased by the Company for each of the months during the fourth quarter of fiscal year ended March 31, 2004:

	<u>Total Number of Shares Purchased</u>	<u>Average Price Paid Per Share</u>	<u>Total Number of Shares Purchased as Part of Publicly Announced Program</u>	<u>Maximum Number of Shares That May Yet Be Purchased Under the Program</u>
January 1 to January 31, 2004	18,850	\$38.49	5,551,107	548,893
February 1 to February 25, 2004	<u>22,321</u>	<u>38.47</u>	<u>5,573,428</u>	<u>526,572</u>
Quarter ended March 31, 2004	<u>41,171</u>	<u>38.48</u>	<u>5,573,428</u>	<u>526,572</u>

In 1996, the Company's Board of Directors authorized the repurchase of up to 100,000 shares of the Company's common stock. Subsequently increased the number of shares authorized to repurchase with the most recent adjustment occurring in April 2002 which increased the number of shares authorized to repurchase to 6,100,000 shares. There is no expiration date for the plan. There were no repurchase plans which either expired or terminated during the period.

Item 6. *Selected Financial Data.*

The selected consolidated financial data of the Company appears in a separate section of this Annual Report on Form 10-K on page 26 and is incorporated herein by this reference.

Item 7. *Management's Discussion and Analysis of Financial Condition and Results of Operations.*

Management's Discussion and Analysis of Financial Condition and Results of Operations appears in a separate section of this Annual Report on Form 10-K beginning on page 27 and is incorporated herein by this reference.

Item 7A. *Quantitative and Qualitative Disclosures About Market Risk.*

As of March 31, 2004, the Company held no market risk sensitive instruments for trading purposes and the Company did not employ any derivative financial instruments, other financial instruments, or derivative commodity instruments to hedge any market risk. The Company had no debt outstanding as of March 31, 2004, and therefore, had no market risk related to debt.

Item 8. *Financial Statements and Supplementary Data.*

The Company's consolidated financial statements, as listed under Item 15, appear in a separate section of this Annual Report on Form 10-K beginning on page 36 and is incorporated herein by this reference. The financial schedule is included below under Item 15.

Item 9. *Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.*

None.

Item 9A. *Controls and Procedures.*

The Company's management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based upon that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, the Company's disclosure controls and procedures were effective in timely alerting them to the material information relating to the Company (or its consolidated subsidiaries) required to be included in the reports the Company files or submits under the Securities Exchange Act of 1934.

Changes in Internal Controls

During the most recent completed fiscal quarter covered by this report, there has been no change in the Company's internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that has materially affected, or is reasonably likely to materially affect, the Company's internal controls over financial reporting.

PART III

Item 10. *Directors and Executive Officers of the Registrant.*

The information required by Item 10 is incorporated herein by reference from the sections titled "Proposal One: Election of Directors," "Directors and Executive Officers of the Company," "Section 16(a) Beneficial Ownership Reporting Compliance" and "Corporate Governance and Board Compensation — Code of Ethics and Business Conduct" appearing in the Company's Definitive Proxy Statement for the 2004 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended March 31, 2004.

Item 11. *Executive Compensation.*

The information required by Item 11 is incorporated herein by reference from the section titled "Executive Compensation", "Compensation Committee Interlocks and Insider Participation", and "Compensation of Directors" except as stated therein, appearing in the Company's Definitive Proxy Statement for the 2004 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended March 31, 2004.

Item 12. *Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters*

The information required by Item 12 is incorporated herein by reference from the section titled "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" and "Equity Compensation Plan Information" appearing in the Company's Definitive Proxy Statement for the 2004 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended March 31, 2004.

Item 13. *Certain Relationships and Related Transactions.*

The information required by Item 13 is incorporated herein by reference from the section titled "Certain Transactions" appearing in the Company's Definitive Proxy Statement for the 2004 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended March 31, 2004.

Item 14. *Principal Accountant Fees and Services*

The information required by Item 14 is incorporated herein by reference from the section titled "Principal Accountant Fees and Services" appearing in the Company's Definitive Proxy Statement for the 2004 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended March 31, 2004.

PART IV

Item 15. *Exhibits, Financial Statement Schedules and Reports on Form 8-K.*

(a) (1) Consolidated Financial Statements:

The Company's consolidated financial statements appear in a separate section of this Annual Report on Form 10-K beginning on the pages referenced below:

	<u>Page</u>
Report of Independent Certified Public Accountants	36
Consolidated Statements of Income for the Years Ended March 31, 2002, 2003, and 2004	37
Consolidated Balance Sheets as of March 31, 2003 and 2004	38
Consolidated Statements of Stockholders' Equity for the Years Ended March 31, 2002, 2003, and 2004	39
Consolidated Statements of Cash Flows for the Years Ended March 31, 2002, 2003, and 2004	40
Notes to Consolidated Financial Statements	41

(2) Financial Statement Schedule:

The Company's consolidated financial statements, as listed under Item 15(a)(1), appear in a separate section of this Annual Report on Form 10-K beginning on page 39. The Company's financial statement schedule is as follows:

Schedule II — Valuation and Qualifying Accounts

	<u>Balance at Beginning of Year</u>	<u>Additions Charged to Costs and Expenses</u>	<u>Deductions</u>	<u>Balance at End of Year</u>
Allowance for doubtful accounts:				
Year Ended March 31, 2002:	\$3,387,000	\$1,967,000	\$(1,719,000)	\$3,635,000
Year Ended March 31, 2003:	3,635,000	1,352,000	(1,514,000)	3,473,000
Year Ended March 31, 2004:	3,473,000	2,100,000	(2,103,000)	3,470,000

(3) Exhibits:

EXHIBITS

<u>Exhibit No.</u>	<u>Title</u>	<u>Method of Filing</u>
3.1	Certificate of Incorporation of the Company	Incorporated herein by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2002.
3.2	Bylaws of the Company	Incorporated herein by reference to Exhibit 3.2 to the Company's Registration Statement on Form S-1 Registration No. 33-40629.
10.1	Nonqualified Stock Option Agreement between V. Gordon Clemons, the Company and North Star together with all amendments and addendums thereto	Incorporated herein by reference to Exhibit 10.6 to the Company's Registration Statement on Form S-1 Registration No. 33-40629.
10.2	Supplementary Agreement between V. Gordon Clemons, the Company and North Star	Incorporated herein by reference to Exhibit 10.7 to the Company's Registration Statement on Form S-1 Registration No. 33-40629.
10.3	Amendment to Supplementary Agreement between Mr. Clemons, the Company and North Star	Incorporated herein by reference to Exhibit 10.5 to the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 1992.
10.4	Restated 1988 Executive Stock Option Plan, as amended	Incorporated herein by reference to Exhibit 10.6 to the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 1995.
10.5	Form of Notice of Grant of Stock Option Under the Restated 1988 Executive Stock Option	Incorporated herein by reference to Exhibit 10.7 to the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 1994.
10.6	Form of Stock Option Agreement under the Restated 1988 Executive Stock Option Plan	Incorporated herein by reference to Exhibit 10.8 to the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 1994.
10.7	Form of Notice of Exercise under the Restated 1988 Executive Stock Option Plan	Incorporated herein by reference to Exhibit 10.9 to the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 1994.
10.8	Employment Agreement of V. Gordon Clemons	Incorporated herein by reference to Exhibit 10.12 to the Company's Registration Statement on Form S-1 Registration No. 33-40629.
10.9	Restated 1991 Employee Stock Purchase Plan, as amended	Incorporated herein by reference to Exhibit 10.11 in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 1995.
10.10	Fidelity Master Plan for Savings and Investment, and amendments	Incorporated herein by reference to Exhibits 10.16 and 10.16A to the Company's Registration Statement on Form S-1 Registration No. 33-40629.
10.15	Shareholder Rights Plan	Incorporated herein by reference to the Company's Form 8-K filed on February 28, 1997.
10.16	Amended Shareholder Rights Plan	Incorporated herein by reference to the Company's Form 8-K filed on May 24, 2002.
21.1	Subsidiaries of the Company	Filed herewith.
23.1	Consent of Independent Certified Public Accountants	Filed herewith.

<u>Exhibit No.</u>	<u>Title</u>	<u>Method of Filing</u>
31.1	Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith.
31.2	Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith.
32.1	Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	Filed herewith.
32.2	Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	Filed herewith.

(b) Reports on Form 8-K during the quarter ended March 31, 2004.

On January 22, 2004, the Company filed a report on Form 8-K to furnish disclosure under Item 12 of the report regarding the Company's press release announcing the Company's financial results for the quarter and nine months ended December 31, 2003.

SIGNATURES

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CORVEL CORPORATION

By: /s/ V. GORDON CLEMONS
V. Gordon Clemons
*Chairman, Chief Executive
Officer and President*

Date: June 14, 2004

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on June 14, 2004.

<u>Signature</u>	<u>Title</u>
<u>/s/ V. GORDON CLEMONS</u> V. Gordon Clemons	Chairman, Chief Executive Officer, and President (Principal Executive Officer)
<u>/s/ RICHARD J. SCHWEPPE</u> Richard J. Schweppe	Chief Financial Officer (Principal Financial and Accounting Officer)
<u>/s/ ALAN HOOPS</u> Alan Hoops	Director
<u>/s/ STEVEN J. HAMERSLAG</u> Steven J. Hamerslag	Director
<u>/s/ JUDD JESSUP</u> Judd Jessup	Director
<u>/s/ JEFFREY J. MICHAEL</u> Jeffrey J. Michael	Director

SELECTED CONSOLIDATED FINANCIAL DATA

The following selected financial data for the five years ended March 31, 2004, have been derived from the Company's audited consolidated financial statements. The following data should be read in conjunction with the Company's Consolidated Financial Statements, the related notes thereto, and "Management's Discussion and Analysis of Financial Condition and Results of Operations." The following amounts are in thousands, except per share data.

	Year Ended March 31,				
	2000	2001	2002	2003	2004
Statement of Income Data:					
Revenues	\$186,765	\$209,554	\$235,912	\$282,776	\$305,279
Costs and Expenses:					
Cost of revenues	152,710	172,010	193,225	230,947	253,846
General and administrative	14,752	16,389	18,783	25,081	26,067
	<u>167,462</u>	<u>188,399</u>	<u>212,008</u>	<u>256,028</u>	<u>279,913</u>
Income before income taxes	19,303	21,155	23,904	26,748	25,366
Income tax provision	7,336	7,933	9,083	10,164	9,353
Net income	<u>\$ 11,967</u>	<u>\$ 13,222</u>	<u>\$ 14,821</u>	<u>\$ 16,584</u>	<u>\$ 16,013</u>
Net income per share:					
Basic	<u>\$.99</u>	<u>\$ 1.16</u>	<u>\$ 1.34</u>	<u>\$ 1.54</u>	<u>\$ 1.51</u>
Diluted	<u>\$.98</u>	<u>\$ 1.13</u>	<u>\$ 1.30</u>	<u>\$ 1.50</u>	<u>\$ 1.48</u>
Shares used in computing net income per share:					
Basic	12,032	11,399	11,043	10,735	10,585
Diluted	12,227	11,672	11,367	11,057	10,838
Return on beginning of year equity	22.5%	23.9%	25.2%	27.2%	23.8%
Return on beginning of year assets	17.4%	18.6%	19.1%	20.7%	16.6%
	<u>2000</u>	<u>2001</u>	<u>2002</u>	<u>2003</u>	<u>2004</u>
Balance Sheet Data as of March 31,					
Cash and cash equivalents	\$ 5,643	\$ 9,457	\$ 12,601	\$ 5,913	\$ 8,641
Accounts receivable, net	35,874	34,316	33,040	45,394	45,538
Working capital	34,396	35,130	35,539	37,513	41,246
Total assets	71,187	77,565	80,295	96,240	106,311
Retained earnings	59,253	72,475	87,296	103,880	119,893
Treasury stock	39,956	53,903	69,140	84,127	96,281
Total stockholders' equity	55,293	58,718	60,983	67,220	77,622

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis of Financial Condition and Results of Operations may include certain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including (without limitation) statements with respect to anticipated future operating and financial performance, growth and acquisition opportunities and other similar forecasts and statements of expectation. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and "should" and variations of these words and similar expressions, are intended to identify these forward-looking statements. Forward-looking statements made by the Company and its management are based on estimates, projections, beliefs and assumptions of management at the time of such statements and are not guarantees of future performance.

The Company disclaims any obligations to update or revise any forward-looking statement based on the occurrence of future events, the receipt of new information or otherwise. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements made by the Company and its management as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions; cost of capital and capital requirements; competition from other managed care companies; the ability to expand certain areas of the Company's business; shifts in customer demands; the ability of the Company to produce market-competitive software; changes in operating expenses including employee wages, benefits and medical inflation; governmental and public policy changes; dependence on key personnel; possible litigation and legal liability in the course of operations; and the continued availability of financing in the amounts and at the terms necessary to support the Company's future business.

Overview

CorVel Corporation is an independent nationwide provider of medical cost containment and managed care services designed to address the escalating medical costs of workers' compensation and auto policies. The Company's services are provided to insurance companies, third-party administrators ("TPA's"), and self-administered employers to assist them in managing the medical costs and monitoring the quality of care associated with healthcare claims.

Network Solutions Services

The Company's Network Solutions services are designed to reduce the price paid by its customers for medical services rendered in workers' compensation cases, and auto policies and, to a lesser extent, group health policies. The network solutions network solutions offered by the Company include automated medical fee auditing, preferred provider services, retrospective utilization review, independent medical examinations, MRI examinations, and inpatient bill review.

Patient Management Services

In addition to its network solutions services, the Company offers a range of patient management services, which involve working on a one-on-one basis with injured employees and their various healthcare professionals, employers and insurance company adjusters. The services designed to monitor the medical necessity and appropriateness of healthcare services provided to workers' compensation and other healthcare claimants and to expedite return to work. The Company offers these services on a stand-alone basis, or as an integrated component of its medical cost containment services.

Organizational Structure

The Company's management is structured geographically with regional vice-presidents who report to the President of the Company. Each of these regional vice-presidents is responsible for all services provided by the Company in his or her particular region and responsible for the operating results of the Company in multiple

states. These regional vice presidents have area and district managers who are also responsible for all services provided by the Company in their given area and district.

Business Enterprise Segments

We operate in one reportable operating segment, managed care. The Company's services are delivered to its customers through its local offices in each region and financial information for the Company's operations follows this service delivery model. All regions provide the Company's patient management and network solutions services. Statement of Financial Accounting Standards, or SFAS No. 131, "Disclosures about Segments of an Enterprise and Related Information," establishes standards for the way that public business enterprises report information about operating segments in annual consolidated financial statements. The Company's internal financial reporting is segmented geographically, as discussed above, and managed on a geographic rather than service line basis, with virtually all of the Company's operating revenue generated within the United States.

Under SFAS 131, two or more operating segments may be aggregated into a single operating segment for financial reporting purposes if aggregation is consistent with the objective and basic principles of SFAS 131, if the segments have similar economic characteristics, and if the segments are similar in each of the following areas: 1) the nature of products and services, 2) the nature of the production processes; 3) the type or class of customer for their products and services; and 4) the methods used to distribute their products or provide their services. We believe each of the Company's regions meet these criteria as they provide the similar services to similar customers using similar methods of productions and similar methods to distribute their services.

Because we believe we meet each of the criteria set forth above and each of our regions have similar economic characteristics, we aggregate our results of operations in one reportable operating segment.

Summary of Annual Results

The Company reported record revenues of \$305 million for fiscal year ended March 31, 2004, an increase of \$22.5 million over fiscal year ended March 31, 2003. However, the Company's sequential revenue increases for the past five quarters have been lower than the Company has historically experienced. The Company's quarterly sequential revenue growth was 1.2% in the March 2003 quarter compared to the December 2002 quarter, followed by quarterly sequential revenue increases of 2.6%, 1.4%, a decrease of 1.7% in the December 2003 quarter, and 1.5% increase in March 2004 quarter compared to the December 2003 quarter. If the revenues from the acquisition of Scan One are eliminated from this calculation, the quarterly sequential revenue increases were 1.2%, 2.5%, 0.5%, a decrease of 1.7% in the December 2003 quarter and an increase of 1.5%, respectively, for the five quarters ended March 31, 2004.

Although the revenues in the quarter ended March 31, 2004 were within \$220,000 of a record for quarter for the Company, the sequential revenue increases reflect the more challenging market conditions and there is no guarantee that the Company will either post revenue growth similar to all previous years or increase revenues. The decline in the manufacturing employment, the decline in workers' compensation claims, the considerable price competition given the flat-to-declining overall market, the increase in competition, changes and the potential changes in state workers' compensation and auto managed care laws which can reduce demand for the Company's services, have created an environment where revenue and margin growth is more difficult to attain and where revenue growth is less certain than historically experienced. Additionally, the Company's technology and preferred provider network competes against other companies, some of which have more resources available. Also, some customers may handle their managed care services in-house and may reduce the amount of services which are outsourced to managed care companies such as CorVel Corporation.

During the fiscal year ended March 31, 2004, the Company achieved a revenue increase of \$22.5 million; however, the Company's expenses increased \$23.9 million. With a challenging revenue environment, the Company will need to keep cost growth at a rate below the revenue growth.

Business Acquisitions During the Three Years Ended March 31, 2004

In May 2002, the Company acquired AnciCare, PPO, Inc., a Florida-based national provider of diagnostic imaging services. The Company paid approximately \$3.4 million (\$2.9 million during fiscal 2003 and \$475,000 during fiscal 2004) and recorded approximately \$3.3 million for goodwill. If the results of the AnciCare operations attain certain revenue during each of the three years after the date of acquisition, the Company will pay an additional amount for the purchase, which is expected to be funded from future earnings generated by the acquisition. Any additional amounts paid will increase the goodwill related to the acquisition. The Company did not attain these revenue milestones during the fiscal 2004 year. As a result, no additional amounts were paid.

In June 2003, the Company expanded its existing office automation service line with the acquisition of Scan One, a provider of scanning, optical character recognition and document management services. The Company expects that this acquisition will provide the opportunity to sell scanning and document management, the services of Scan One, through a number of the Company's larger offices. The Company believes these services are synergistic with the Company's medical bill review processing.

Results of Operations

The Company derives its revenues from providing patient management and network solutions services to payors of workers' compensation benefits, auto insurance claims and health insurance benefits. Patient management services include utilization review, medical case management, and vocational rehabilitation. Network solutions revenues include fee schedule auditing, hospital bill auditing, independent medical examinations, diagnostic imaging review services and preferred provider referral services. In the prior fiscal years, the Company included the revenue from utilization review with network solutions revenues. The Company determined it was more appropriate to include these revenues with patient management. The revenue mix percentages shown below have been adjusted to include utilization review with the patient management services revenue. This change did not affect the trend of the past few years of slow growth in the patient management services causing this service to represent a lesser portion of the Company's revenues. The percentages of revenues attributable to patient management and network solutions services for the fiscal years ended March 31, 2002, 2003, and 2004 are listed below.

	<u>2002</u>	<u>2003</u>	<u>2004</u>
Patient management services	56.0%	49.2%	45.2%
Network solutions services	<u>44.0%</u>	<u>50.8%</u>	<u>54.8%</u>
	<u>100.0%</u>	<u>100.0%</u>	<u>100.0%</u>

Income Statement Percentages

The following table sets forth, for the periods indicated, the percentage of revenues represented by certain items reflected in the Company's consolidated statements of income. The Company's past operating results are not necessarily indicative of future operating results.

	<u>Year Ended March 31,</u>		
	<u>2002</u>	<u>2003</u>	<u>2004</u>
Revenues	100.0%	100.0%	100.0%
Cost of revenues	81.9	81.7	83.2
Gross profit	18.1	18.3	16.8
General and administrative	8.0	8.9	8.5
Income before income taxes	10.1	9.4	8.3
Net income	6.3	5.9	5.2

Revenue

Change in Revenue

2003 Compared to 2002

Revenues for fiscal 2003 increased by 20% to \$283 million from \$236 million in fiscal 2002, an increase of \$47 million. The majority of this growth came from network solutions services, which grew 38% from \$104 million in fiscal year 2002 to \$144 million in fiscal 2003, primarily due to an increase in the number of bills reviewed and, to a lesser extent, an increase in the number of providers included in the Company's PPO network. Of this \$40 million increase, \$12 million was due to the aforementioned acquisition of Ancicare, a national provider of diagnostic imaging services, in May 2002. Patient management services increased 5%, by \$7 million from \$132 million in fiscal 2002 to \$139 million in fiscal 2003. This increase was due primarily to an increase in pricing and, to a lesser extent, a nominal increase in the case referral volume.

Change in Revenue

2004 Compared to 2003

Revenues for fiscal year 2004 increased by 8% to \$305 million, from \$283 million in fiscal year 2003, an increase of \$23 million. The majority of this growth came from network solutions services, which grew 17% from \$144 million in fiscal year 2003 to \$167 million in fiscal year 2004. Approximately half of this increase was due to an increase in the CorcareRx services which increased from \$3 million to \$15 million. The CorcareRx service margins are the lowest amongst the network solutions services which contributed to the decrease in the Company's gross profit margin.

Additionally, \$2 million of the revenue increase was due to the acquisition of Scan One, a document imaging company, which is integrated with the bill review services. Revenue from patient management services decreased less than 1% from fiscal 2003 to fiscal 2004.

Cost of Revenue

The Company's cost of revenues consist of direct expenses, costs directly attributable to the generation of revenue, and field indirect costs which are incurred in the field to support the operations in the field offices which generate the revenue. Direct costs are primarily case manager salaries, bill review analysts, related payroll taxes and fringe benefits, and costs for IME (independent medical examination) and MRI providers. Most of the Company's revenues are generated in offices which provide both patient management services and network solutions services. The largest of the field indirect costs are manager salaries and bonus, account executive base pay and commissions, administrative and clerical support, field systems personnel, PPO network developers, related payroll taxes and fringe benefits, office rent, and telephone expense. Approximately 40% of the costs incurred in the field are field indirect costs which support both the patient management services and network solutions operations of the Company's field operations.

Change in Cost of Revenue

2003 Compared to 2002

Cost of revenues increased from \$193 million to \$231 million, an increase of \$38 million or 19.5% compared to revenue growth of 19.9%. The largest components of the direct costs are direct salaries for case managers and bill review analysts which increased by \$6 million, or 9%, from \$67 million to \$73 million and IME and MRI provider costs which increased by \$13 million, or 76%, from \$17 million to \$30 million. IME and MRI provider costs increased due to the increase in these revenues.

The largest components of the field indirect costs and the changes from fiscal 2002 to fiscal 2003 are: manager salaries, which increased by \$2 million, or 13%, from \$16 million to \$18 million; clerical salaries, which increased by \$3 million, from \$15 million to \$18 million; and rent which increased by \$1 million from \$9 million to \$10 million.

Change in Cost of Revenue

2004 Compared to 2003

Cost of revenues increased from \$231 million to \$254 million, an increase of \$23 million or 10% compared to revenue growth of 8%. Cost of revenues increased by a greater actual dollar and greater percentage than revenue. This increase in cost of revenues exceeded the increase in revenues on a percentage and absolute dollar basis because approximately half of the revenue growth in fiscal 2004 is from CorcareRX which has low gross margins. The largest components of the direct costs are direct salaries for case managers and bill review analysts which increased by \$1 million, or 1%, from \$73 million to \$74 million because of the limited increase in bill volume processed and lack of growth in case management referrals. IME and MRI provider costs increased by \$6 million, or 20%, from \$30 million to \$36 million. CorcareRX provider costs increased by \$11 million, from \$3 million to \$14 million, due to the increase in revenues noted above.

The largest components of the field indirect costs and the changes from fiscal 2003 to fiscal 2004 are: manager salaries, which remained relatively unchanged at approximately \$18.5 million for both fiscal 2003 and 2004; and clerical salaries, which increased by \$1 million, from \$18 million to \$19 million. The growth in the field salary costs was nominal as the Company reduced the field headcount (excluding the acquisition of Scan One) by over 200 employees from December 2002 to March 2004.

General and Administrative Costs

Change in General and Administrative Costs

2003 Compared to 2002

General and administrative costs consist primarily of corporate systems costs which include national support, software development and implementation, software training, the Company's national wide area network and other systems related costs. The rest of the general and administrative costs consist of national marketing, national sales support, corporate legal, insurance, human resources, accounting and other general corporate matters.

General and administrative expense increased from \$19 million in fiscal 2002 to \$25 million in fiscal 2003. General and administrative costs were 8% and 9% of revenues for these years, respectively. Most of this increase was due to increase in systems costs from \$10 million in fiscal 2002 to \$15 million in fiscal 2003, primarily due to increased MIS staff to support the Company's implementation of Care^{MC} and further electronic data interface capabilities as required by customer needs. Systems costs were 4% and 5% of revenues for fiscal 2002 and 2003, respectively. Other general and administrative costs increased from \$9 million to \$10 million, and were 4% of revenues in each of fiscal 2002 and 2003.

Change in General and Administrative Costs

2004 Compared to 2003

General and administrative expense increased from \$25 million in fiscal 2003 to \$26 million in fiscal 2004. General and administrative costs were 9% of revenues for each of these two years. Almost all of this increase was due to increase in systems costs from \$15 million in fiscal 2003 to \$16 million in fiscal 2004, was primarily due to increased staff for field support and for customer needs. Systems costs were approximately 5% of revenues for fiscal 2003 and 2004, respectively. Other general and administrative costs remained unchanged at \$10 million from fiscal 2003 to fiscal 2004.

Income Tax Provision

The Company's income tax expense for fiscal 2002, fiscal 2003, and fiscal 2004 were \$9 million, \$10 million, and \$9 million, respectively. The increase in the income tax expense for fiscal 2003 and subsequent decrease in fiscal 2004 resulted primarily from an increase in income before income taxes in fiscal 2003 and a decrease in income before income taxes from fiscal 2003 to fiscal 2004. The effective income tax rates for fiscal 2002, fiscal 2003, and fiscal 2004 were 38%, 38% and 37%, respectively. This rate differed from

the statutory federal tax rate of 35.0% primarily due to state income taxes and certain non-deductible expenses.

Liquidity and Capital Resources

The Company has historically funded its operations and capital expenditures primarily from cash flow from operations, and to a lesser extent, option exercises. Net working capital increased from \$38 million to \$41 million, primarily due to an increase in cash from \$6 million to \$9 million. This increase in cash is primarily due to an increase in cash provided by operating activities from \$22 million in fiscal 2003 to \$28 million in fiscal 2004 along with a reduction in the amount spent to repurchase the Company's common stock from \$15 million in fiscal 2003 to \$12 million in fiscal 2004.

The Company believes that cash from operations, existing working capital, line of credit, and funds from exercise of stock options granted to employees are adequate to fund existing obligations, repurchase shares of the Company's common stock, introduce new services, and continue to develop healthcare related businesses. The Company regularly evaluates cash requirements for current operations and commitments, and for capital acquisitions and other strategic transactions. The Company may elect to raise additional funds for these purposes, either through debt or additional equity, the sale of investment securities or otherwise, as appropriate.

As of March 31, 2004, the Company had \$9 million in cash and cash equivalents, invested primarily in short-term, highly liquid investments with maturities of 90 days or less.

In April 2003, the Company entered into a credit agreement with a financial institution to provide borrowing capacity of up to \$5 million. This agreement expires in September 2004. Borrowings under this agreement bear interest, at the Company's option, at a fluctuating LIBOR-based rate plus 1.25% or at the financial institution's prime lending rate. There were no outstanding borrowings against this line of credit at either March 31, 2003 or March 31, 2004. The loan covenants require the Company to maintain a quick ratio of at least 2:1, a tangible net equity of at least \$45 million and have positive net income.

The Company has historically required substantial capital to fund the growth of its operations, particularly working capital to fund the growth in accounts receivable and capital expenditures. The Company believes, however, that the cash balance at March 31, 2004 along with anticipated internally generated funds and the available line of credit would be sufficient to meet the Company's expected cash requirements for at least the next twelve months.

Contractual Obligations

The following table set forth our contractual obligations at March 31, 2004, which are future minimum lease payments due under noncancelable operating leases:

	<u>Total</u>	<u>2005</u>	<u>2006 - 2007</u>	<u>2008 - 2009</u>	<u>After 2009</u>
Operating Leases.....	<u>\$34,262,000</u>	<u>\$9,803,000</u>	<u>\$16,507,000</u>	<u>\$7,593,000</u>	<u>\$359,000</u>

Operating Cash Flows

2003 Compared to 2002

Net cash provided by operating activities was \$27 million in 2002 compared to \$21 million in 2003. The decrease in operating cash flows of \$6 million was primarily due to the increase in the number of days sales outstanding (DSO) in accounts receivable from 50 days at March 31, 2002 from 56 days at March 31, 2003 which was partially caused by the Company's transition of its accounts receivable from its legacy system to a Peoplesoft system. The migration effort between these two systems distracted from the Company's ongoing collection efforts. Of the \$10 million increase in accounts receivable from fiscal 2002 to fiscal 2003, \$5 million was due to the increase in revenues and \$5 million was due to the increase in days sales outstanding. Net income increased from \$15 million in 2002 to \$17 million in 2003.

Operating Cash Flows

2004 Compared to 2003

Net cash provided by operating activities was \$21 million in 2003 compared to \$26 million in 2004. The improvement in cash flow from operations of \$6 million was primarily due to the improvement in the accounts receivable days sales outstanding from 56 days at March 31, 2003 to 54 days at March 31, 2004. During the prior fiscal year, an increase in accounts receivable created a \$10 million use in cash from operating activities. Because the fiscal year 2004 revenue increase was less than the fiscal year 2003 revenue increase and the days sales outstanding decreased, accounts receivable, excluding the accounts receivable acquired in the Scan One acquisition decreased from fiscal 2003 to fiscal 2004.

Investing Activities

2003 Compared to 2002

Net cash flow used in investing activities was \$11 million in fiscal 2002 compared to \$17 million in fiscal 2003. The increase in cash flow used in investing activities was primarily due to the \$3 million investment in the acquisition of Ancicare, noted above, and to a lesser extent an increase in purchases of property and equipment from \$11 million in fiscal 2002 to \$14 million in fiscal 2003.

Investing Activities

2004 Compared to 2003

Net cash flow used in investing activities was \$17 million both fiscal 2003 and fiscal 2004 in both business acquisitions and property additions. The Company paid \$4 million for acquired businesses, including an additional \$.5 million payment for the Ancicare acquisition, noted above, along with \$3.7 in disbursements to acquire the stock of Scan One, as noted above, and to pay off the outstanding notes payable of Scan One. Purchases of property and equipment decreased from \$14 million in fiscal 2003 to \$13 million in fiscal 2004 partially due to the reduction in the growth in the Company's revenues.

Financing Activities

2003 Compared to 2002

Net cash flow used in financing activities was \$13 million in 2002 compared to \$10 million in 2003. The decrease in cash flow used in financing activities was primarily due to an increase in the amount of cash generated from the proceeds from the exercise of employee stock options and the employee stock purchase plan from \$2 million in 2002 to \$3 million in 2003, and to a lesser extent an increase in the tax benefit from the exercise of stock options.

During both fiscal 2002 and fiscal 2003, the Company used \$15 million in repurchasing its common stock. The Company repurchased 557,870 shares in fiscal 2002 and 461,527 shares in fiscal 2003. In 1996, the Company's Board of Directors authorized the repurchase of the Company's common stock. Including an expansion authorized in April 2002, the total number of shares authorized to repurchase has now been increased to 6,100,000 shares.

Financing Activities

2004 Compared to 2003

Net cash flow used in financing activities was \$10 million in 2003 compared to \$6 million in 2004. The decrease in cash flow used in financing activities was primarily due to a \$1 million increase in the amount of cash generated from the proceeds from the exercise of options in common stock and to a lesser extent an increase in the tax benefit from the exercise of stock options from \$1 million in fiscal 2003 to \$2 million in fiscal 2004 along with a decrease in the amount spent by the Company to repurchase its common stock from \$15 million in fiscal 2003 to \$12 million in fiscal 2004. Additionally, the tax benefits from stock option

exercises increased due to an increase in the number of options exercised from 205,000 to 277,000, respectively, along with a higher average stock price which increased the amount of tax deduction from the exercise of the stock options. The Company repurchased 461,527 shares in fiscal 2003 and 342,121 shares in fiscal 2004.

Critical Accounting Policies

The SEC defines critical accounting policies as those that require application of management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.

The following is not intended to be a comprehensive list of our accounting policies. Our significant accounting policies are more fully described in Note A to the Consolidated Financial Statements. In many cases, the accounting treatment of a particular transaction is specifically dictated by accounting principles generally accepted in the United States of America, with no need for management's judgment in their application. There are also areas in which management's judgment in selecting an available alternative would not produce a materially different result.

We have identified the following accounting policies as critical to us: 1) revenue recognition, 2) allowance for uncollectible accounts, 3) valuation of long-lived assets, 4) accrual for self-insured costs, and 5) accounting for income taxes.

Revenue Recognition: The Company's revenues are recognized primarily as services are rendered based on time and expenses incurred. A certain portion of the Company's revenues are derived from fee schedule auditing which is based on the number of provider charges audited and, to a lesser extent, on a percentage of savings achieved for the Company's clients.

Allowance for Uncollectible Accounts: The Company determines its allowance by considering a number of factors, including the length of time trade accounts receivable are past due, the Company's previous loss history, the customers' current ability to pay its obligation to the Company, and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.

Valuation of Long-lived Assets: We assess the impairment of identifiable intangibles, property, plant and equipment, goodwill and investments whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important which could trigger an impairment review include the following:

- significant underperformance relative to expected historical or projected future operating results;
- significant changes in the manner of our use of the acquired assets or the strategy for our overall business;
- significant negative industry or economic trends;
- significant decline in our stock price for a sustained period; and
- our market capitalization relative to net book value.

When we determine that the carrying value of intangibles, long-lived assets and related goodwill may not be recoverable based upon the existence of one or more of the above indicators of impairment, impairments are recognized when the expected future undiscounted cash flows derived from such assets are less than their carrying value, except for investments. We generally measure any impairment based on a projected discounted cash flow method using a discount rate determined by our management to be commensurate with the risk inherent in our current business model. A loss in the value of an investment will be recognized when it is determined that the decline in value is other than temporary.

Accrual for Self-insurance Costs: The Company self-insures for the group medical costs and workers' compensation costs of its employees. The Company purchases stop loss insurance for large claims. Management believes that the self-insurance reserves are appropriate; however, actual claims costs may differ from the original estimates requiring adjustments to the reserves.

Accounting for Income Taxes: As part of the process of preparing our consolidated financial statements we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves us estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from future taxable income and to the extent we believe that recovery is not likely, we must establish a valuation allowance. If the Company was to establish a valuation allowance or increase this allowance in a period, the Company must include an expense within the tax provision in the consolidated statement of income. Significant management judgment is required in determining our provision for income taxes and our deferred tax assets and liabilities.

Recently Issued Accounting Standards

In May of 2003, the Financial Accounting Standards Board (the Board), issued SFAS 150 *Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity* (SFAS 150). This Statement establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. It requires that an issuer classify a financial instrument that is within its scope as a liability (or an asset in some circumstances). Many of those instruments would previously have been classified as equity. This Statement is effective for financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003, except for mandatorily redeemable financial instruments of nonpublic entities. The Company has reviewed the provisions of SFAS 150, and believes that it does not have any financial instruments requiring reclassifications under SFAS 150.

In January 2003, the Board issued FASB Interpretation No. 46 (FIN 46), *Consolidation of Variable Interest Entities — an Interpretation of ARB No. 51, Consolidated Financial Statements*. The Interpretation addresses how variable interest entities are to be identified and how an enterprise assesses its interests in a variable interest entity to decide whether to consolidate that entity. The Interpretation also requires existing unconsolidated variable interest entities to be consolidated by their primary beneficiaries if the entities do not effectively disperse risks among the parties involved. FIN 46 is effective in the first fiscal year or interim period beginning after June 15, 2003, to variable interest entities in which a company holds a variable interest that is acquired before February 1, 2003. The provisions of FIN 46 have been reviewed, and the Company does not believe that it has any entities requiring consolidation.

REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

Stockholders and Board of Directors
CorVel Corporation

We have audited the accompanying consolidated balance sheets of CorVel Corporation as of March 31, 2003 and 2004, and the related consolidated statements of income, stockholders' equity, and cash flows for each of the three years in the period ended March 31, 2004. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of CorVel Corporation as of March 31, 2003 and 2004, and the consolidated results of their operations and their consolidated cash flows for each of the three years in the period ended March 31, 2004, in conformity with accounting principles generally accepted in the United States of America.

We have also audited Schedule II of CorVel Corporation for each of the three years in the period ended March 31, 2004. In our opinion, this schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly, in all material respects, the information therein.

/s/ GRANT THORNTON LLP

Portland, Oregon
May 10, 2004

CORVEL CORPORATION
CONSOLIDATED STATEMENTS OF INCOME

	Years Ended March 31,		
	2002	2003	2004
REVENUES	\$235,912,000	\$282,776,000	\$305,279,000
COSTS AND EXPENSES			
Cost of revenues	193,225,000	230,947,000	253,846,000
General and administrative	18,783,000	25,081,000	26,067,000
	<u>212,008,000</u>	<u>256,028,000</u>	<u>279,913,000</u>
Income before income taxes	23,904,000	26,748,000	25,366,000
Income tax provision	9,083,000	10,164,000	9,353,000
NET INCOME	<u>\$ 14,821,000</u>	<u>\$ 16,584,000</u>	<u>\$ 16,013,000</u>
Net income per share:			
Basic	<u>\$ 1.34</u>	<u>\$ 1.54</u>	<u>\$ 1.51</u>
Diluted	<u>\$ 1.30</u>	<u>\$ 1.50</u>	<u>\$ 1.48</u>
Shares used in computing net income per share:			
Basic	11,043,000	10,735,000	10,585,000
Diluted	11,367,000	11,057,000	10,838,000

See accompanying notes to consolidated financial statements.

CORVEL CORPORATION
CONSOLIDATED BALANCE SHEETS

	March 31,	
	<u>2003</u>	<u>2004</u>
ASSETS		
Current Assets		
Cash and cash equivalents	\$ 5,913,000	\$ 8,641,000
Accounts receivable (less allowance for doubtful accounts of \$3,473,000 in 2003 and \$3,470,000 in 2004)	45,394,000	45,538,000
Prepaid expenses and taxes	4,730,000	5,363,000
Deferred income taxes	<u>5,029,000</u>	<u>4,316,000</u>
Total current assets	<u>61,066,000</u>	<u>63,858,000</u>
Property and equipment, net	25,848,000	29,387,000
Goodwill	8,868,000	12,562,000
Other assets	<u>458,000</u>	<u>504,000</u>
	<u>\$ 96,240,000</u>	<u>\$106,311,000</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities		
Accounts and taxes payable	\$ 9,795,000	\$ 10,765,000
Accrued liabilities	<u>13,758,000</u>	<u>11,847,000</u>
Total current liabilities	<u>23,553,000</u>	<u>22,612,000</u>
Deferred income taxes	5,467,000	6,077,000
Commitments and Contingencies (Note H)	—	—
Stockholders' Equity		
Common Stock, \$.0001 par value: 20,000,000 shares authorized; 15,857,676 (10,626,369, net of Treasury shares) and 16,163,104 shares (10,589,676, net of the Treasury shares) issued and outstanding in 2003 and 2004, respectively	2,000	2,000
Paid-in Capital	47,465,000	54,008,000
Treasury Stock, at cost (5,231,307 shares in 2003 and 5,573,428 shares in 2004)	(84,127,000)	(96,281,000)
Retained Earnings	<u>103,880,000</u>	<u>119,893,000</u>
Total stockholders' equity	<u>67,220,000</u>	<u>77,622,000</u>
	<u>\$ 96,240,000</u>	<u>\$106,311,000</u>

See accompanying notes to consolidated financial statements.

CORVEL CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Years Ended March 31, 2002, 2003, and 2004

	<u>Common Stock — Shares</u>	<u>Common Stock — Amount</u>	<u>Paid-In- Capital</u>	<u>Treasury Stock</u>	<u>Treasury Stock — Cost</u>	<u>Retained Earnings</u>	<u>Total Shareholders' Equity</u>
Balance — March 31, 2001	15,444,704	\$2,000	\$40,144,000	(4,211,910)	\$(53,903,000)	\$ 72,475,000	\$ 58,718,000
Stock issued under employee stock purchase plan	36,951		788,000				788,000
Stock issued and income tax benefits under stock option plan, net of shares repurchased	135,726		1,893,000				1,893,000
Purchase of common stock				(557,870)	(15,237,000)		(15,237,000)
Net income						14,821,000	14,821,000
Balance — March 31, 2002	15,617,381	2,000	42,825,000	(4,769,780)	(69,140,000)	87,296,000	60,983,000
Stock issued under employee stock purchase plan	37,147		952,000				952,000
Stock issued and income tax benefits under stock option plan, net of shares repurchased	203,148		3,688,000				3,688,000
Purchase of common stock				(461,527)	(14,987,000)		(14,987,000)
Net income						16,584,000	16,584,000
Balance — March 31, 2003	15,857,676	2,000	47,465,000	(5,231,307)	(84,127,000)	103,880,000	67,220,000
Stock issued under employee stock purchase plan	39,295		1,143,000				1,143,000
Stock issued and income tax benefits under stock option plan, net of shares repurchased	266,133		5,400,000				5,400,000
Purchase of common stock				(342,121)	(12,154,000)		(12,154,000)
Net income						16,013,000	16,013,000
Balance — March 31, 2004	16,163,104	\$2,000	\$54,008,000	(5,573,428)	\$(96,281,000)	\$119,893,000	\$ 77,622,000

See accompanying notes to consolidated financial statements.

CORVEL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS

	Years Ended March 31,		
	2002	2003	2004
CASH FLOWS FROM OPERATING ACTIVITIES			
Net income	\$ 14,821,000	\$ 16,584,000	\$ 16,013,000
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	8,414,000	9,339,000	9,958,000
Loss on write down or disposal of property or capitalized software	52,000	1,500,000	—
Deferred income taxes	(40,000)	999,000	1,329,000
Changes in operating assets and liabilities:			
Accounts receivable	1,276,000	(9,778,000)	159,000
Prepaid expenses and taxes	1,166,000	(3,431,000)	(536,000)
Accounts and taxes payable	426,000	2,800,000	783,000
Accrued liabilities	(27,000)	1,553,000	(1,975,000)
Other assets	488,000	1,417,000	(42,000)
Net cash provided by operating activities	<u>26,576,000</u>	<u>20,983,000</u>	<u>25,689,000</u>
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisition of business, net of cash acquired	—	(3,395,000)	(4,228,000)
Purchases of property and equipment	<u>(10,876,000)</u>	<u>(13,929,000)</u>	<u>(13,122,000)</u>
Net cash used in investing activities	<u>(10,876,000)</u>	<u>(17,324,000)</u>	<u>(17,350,000)</u>
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from employee stock purchase plan	788,000	952,000	1,143,000
Proceeds from exercise of stock options	1,287,000	2,423,000	3,365,000
Tax benefits from stock options exercised	606,000	1,265,000	2,035,000
Purchase of common stock	<u>(15,237,000)</u>	<u>(14,987,000)</u>	<u>(12,154,000)</u>
Net cash used in financing activities	<u>(12,556,000)</u>	<u>(10,347,000)</u>	<u>(5,611,000)</u>
Net increase (decrease) in cash and cash equivalents	3,144,000	(6,688,000)	2,728,000
Cash and cash equivalents at beginning of year	<u>9,457,000</u>	<u>12,601,000</u>	<u>5,913,000</u>
CASH AND CASH EQUIVALENTS AT END OF YEAR	<u>\$ 12,601,000</u>	<u>\$ 5,913,000</u>	<u>\$ 8,641,000</u>

See accompanying notes to consolidated financial statements.

CORVEL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2004

Note A — Summary of Significant Accounting Policies

Organization: CorVel Corporation (CorVel or the Company) provides services and programs nationwide that are designed to enable insurance carriers, third party administrators and employers with self-insured programs to administer, manage and control the cost of workers' compensation and other healthcare benefits.

Basis of Presentation: The consolidated financial statements include the accounts of CorVel and its subsidiaries. Significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates: The preparation of financial statements in conforming with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.

Cash and Cash Equivalents: Cash and cash equivalents consists of short-term highly-liquid investments with maturities of 90 days or less when purchased. The carrying amounts of the Company's financial instruments approximate their fair values at March 31, 2003 and 2004.

Revenue Recognition: The Company's revenues are recognized primarily as services are rendered based on time and expenses incurred. A certain portion of the Company's revenues are derived from fee schedule auditing which is based on the number of provider charges audited and, to a limited extent, on a percentage of savings achieved for the Company's clients. Accounts receivable includes \$3,808,000 and \$3,145,000 of unbilled receivables at March 31, 2003 and 2004, respectively. No one customer accounted for more than 10% of consolidated revenues during the years ended March 31, 2002, 2003 and 2004.

Accounts Receivable: The majority of the Company's accounts receivable are due from companies in the property and casualty insurance industries. Credit is extended based on evaluation of a customer's financial condition and, generally, collateral is not required. Accounts receivable are due within 30 days and are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering a number of factors, including the length of time trade accounts receivable are past due, the Company's previous loss history, the customer's current ability to pay its obligation to the Company, and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.

Property and Equipment: Additions to property and equipment are recorded at cost. Depreciation and amortization are provided using the straight-line and accelerated methods over the estimated useful lives of the related assets, which range from three to seven years.

The Company capitalized software development costs intended for internal use. The capitalized software was \$8,505,000 (net of \$12,788,000 in accumulated amortization) as of March 31, 2003, and was \$10,306,000, (net of \$14,644,000 in accumulated amortization) as of March 31, 2004. These costs are included in computer software in property and equipment and are amortized over a period of five years.

Long-Lived Assets: The carrying amount of all long-lived assets is evaluated periodically to determine if adjustment to the depreciation and amortization period or to the unamortized balance is warranted. Such evaluation is based principally on the expected utilization of the long-lived assets and the projected, undiscounted cash flows of the operations in which the long-lived assets are deployed.

Goodwill: In contrast to accounting standards in effect during 2002, Statement of Financial Accounting Standards (SFAS) No. 142, *Goodwill and Other Intangible Assets*, which became effective beginning in 2003, provides that goodwill, as well as identifiable intangible assets with indefinite lives, should not be amortized.

CORVEL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Accordingly, with the adoption of SFAS 142 on April 1, 2002, the Company discontinued the amortization of goodwill and indefinite-lived intangibles. In addition, useful lives of intangible assets with finite lives were reevaluated on adoption of SFAS 142. The information presented below reflects adjustments to information reported in 2002 as if SFAS 142 had been applied. The adjustments include the effects of not amortizing goodwill and indefinite-lived intangible assets and the modification in the estimated useful lives of intangible assets with finite lives. Goodwill amounted to \$8,868,000 (net of accumulated amortization of \$2,047,000) at March 31, 2003 and \$12,562,000 (net of accumulated amortization of \$2,047,000) at March 31, 2004.

The following table reflects the effect of SFAS 142 on net income and earnings per share as if SFAS 142 had been in effect for fiscal years ending March 31, 2002, 2003, and 2004:

	2002	2003	2004
Net income	\$14,821,000	\$16,584,000	\$16,013,000
Add back: goodwill amortization	244,000	—	—
Adjusted net income	<u>\$15,065,000</u>	<u>\$16,584,000</u>	<u>\$16,013,000</u>
Basic net income per share:			
Reported net income	\$ 1.34	\$ 1.54	\$ 1.51
Goodwill amortization02	—	—
Adjusted net income per share	<u>\$ 1.36</u>	<u>\$ 1.54</u>	<u>\$ 1.51</u>
Diluted net income per share:			
Reported net income	\$ 1.30	\$ 1.50	\$ 1.48
Goodwill amortization03	—	—
Adjusted net income per share	<u>\$ 1.33</u>	<u>\$ 1.50</u>	<u>\$ 1.48</u>

Concentrations of Credit Risk: The Company performs periodic credit evaluations of its customers' financial condition and does not require collateral. No single customer accounted for more than 10% of accounts receivable in 2003 or 2004. Receivables are generally due within 30 days. Credit losses relating to customers in the workers' compensation insurance industry consistently have been within management's expectations.

Income Taxes: The Company provides for income taxes under the liability method. Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities as measured by the enacted tax rates which are expected to be in effect when these differences reverse. Income tax expense is the tax payable for the period and the change during the period in net deferred tax assets and liabilities.

Earnings Per Share: Earnings per common share-basic is based on the weighted average number of common shares outstanding during the period. Earnings per common shares-diluted is based on the weighted average number of common shares and common share equivalents outstanding during the period. In calculating earnings per share, earnings are the same for the basic and diluted calculations. Weighted average shares outstanding increased for diluted earnings per share due to the effect of stock options.

The Company derives the majority of its revenues from providing patient management and network solutions services to payors of workers' compensation benefits, auto insurance claims and health insurance benefits. Patient management services include utilization review, medical case management, and vocational rehabilitation. Network solutions revenues include fee schedule auditing, hospital bill auditing, independent medical examinations, diagnostic imaging review services and preferred provider referral services. In the prior fiscal years, the Company included the revenue from utilization review with network solutions revenues. The

CORVEL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

revenue mix percentages shown below have been adjusted to include utilization review with the patient management services revenue. The percentages of revenues attributable to patient management and network solutions services for the fiscal years ended March 31, 2002, 2003, and 2004 are listed below.

	<u>2002</u>	<u>2003</u>	<u>2004</u>
Patient management services	56.0%	49.2%	45.2%
Network solutions services	<u>44.0%</u>	<u>50.8%</u>	<u>54.8%</u>
	<u>100.0%</u>	<u>100.0%</u>	<u>100.0%</u>

generated within the United States. As noted above, all regions provide the Company's patient management and network solutions services.

Under SFAS 131, two or more operating segments may be aggregated into a single operating segment for financial reporting purposes if aggregation is consistent with the objective and basic principles of SFAS 131, if the segments have similar economic characteristics, and if the segments are similar in each of the following areas: 1) the nature of products and services, 2) the nature of the production processes; 3) the type or class of customer for their products and services; and 4) the methods used to distribute their products or provide their services. Each of the Company's regions meet these criteria as they provide the similar services to similar customers using similar methods of productions and similar methods to distribute their services.

Because we meet each of the criteria set forth above and each of our regions have similar economic characteristics, we aggregate our results of operations in one reportable operating segment.

The Company derives the majority of its revenues from providing patient management and network solutions services to payors of workers' compensation benefits, auto insurance claims and health insurance benefits. Patient management services include utilization review, medical case management, and vocational rehabilitation. Network solutions revenues include fee schedule auditing, hospital bill auditing, independent medical examinations, diagnostic imaging review services and preferred provider referral services. In the prior fiscal years, the Company included the revenue from utilization review with network solutions revenues. The revenue mix percentages shown below have been adjusted to include utilization review with the patient management services revenue. The percentages of revenues attributable to patient management and network solutions services for the fiscal years ended March 31, 2002, 2003, and 2004 are listed below.

	<u>2002</u>	<u>2003</u>	<u>2004</u>
	56.0%	49.2%	45.2%
	44.0%	50.8%	54.8%
Patient management services	—	—	—
Network solutions services	<u>100.0%</u>	<u>100.0%</u>	<u>100.0%</u>

Stock Based Compensation Plans: The Company has a stock-based employee compensation plan, which is described more fully in Note E. The Company applies APB Opinion 25, *Accounting for Stock Issued to Employees*, and related Interpretations in accounting for its plans. The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of

CORVEL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

SFAS 123, *Accounting for Stock-Based Compensation*, using the assumptions described in Note E, to its stock-based employee plans.

	<u>2002</u>	<u>2003</u>	<u>2004</u>
Net income	\$14,821,000	\$16,584,000	\$16,013,000
Deduct: Stock-based employee compensation cost, net of taxes	<u>805,000</u>	<u>881,000</u>	<u>861,000</u>
Pro forma net income	<u>\$14,016,000</u>	<u>\$15,703,000</u>	<u>\$15,152,000</u>
Earnings per share — basic			
As reported	\$ 1.34	\$ 1.54	\$ 1.51
Pro forma	\$ 1.27	\$ 1.46	\$ 1.43
Earnings per share — diluted			
As reported	\$ 1.30	\$ 1.50	\$ 1.48
Pro forma	\$ 1.23	\$ 1.42	\$ 1.40

Reclassifications: Certain amounts in the 2002 and 2003 consolidated financial statements and notes to the consolidated financial statements have been reclassified to conform to the 2004 presentation. The reclassifications have no effect on total revenues, total expenses, net income or stockholders' equity, as previously reported.

Recently Issued Accounting Pronouncements: In May of 2003, the Financial Accounting Standards Board (the Board), issued SFAS 150 *Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity* (SFAS 150). This Statement establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. It requires that an issuer classify a financial instrument that is within its scope as a liability (or an asset in some circumstances). Many of those instruments would previously have been classified as equity. This Statement is effective for financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003, except for mandatorily redeemable financial instruments of nonpublic entities. The Company has reviewed the provisions of SFAS 150, and believes that it does not have any financial instruments requiring reclassifications under SFAS 150.

In January 2003, the Board issued FASB Interpretation No. 46 (FIN 46), *Consolidation of Variable Interest Entities — an Interpretation of ARB No. 51, Consolidated Financial Statements*. The Interpretation addresses how variable interest entities are to be identified and how an enterprise assesses its interests in a variable interest entity to decide whether to consolidate that entity. The Interpretation also requires existing unconsolidated variable interest entities to be consolidated by their primary beneficiaries if the entities do not effectively disperse risks among the parties involved. FIN 46 is effective in the first fiscal year or interim period beginning after June 15, 2003, to variable interest entities in which a company holds a variable interest that is acquired before February 1, 2003. The provisions of FIN 46 have been reviewed, and the Company does not believe that it has any entities requiring consolidation.

CORVEL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Note B — Property and Equipment

Property and equipment consists of the following at March 31:

	2003	2004
Office equipment and computers	\$36,443,000	\$39,916,000
Computer software	26,655,000	30,836,000
Leasehold improvements	2,481,000	3,161,000
	65,579,000	73,913,000
Less: accumulated depreciation and amortization	39,731,000	44,526,000
	<u>\$25,848,000</u>	<u>\$29,387,000</u>

Note C — Accrued Liabilities

Accrued liabilities consist of the following at March 31:

	2003	2004
Payroll and related benefits	\$ 9,384,000	\$ 7,061,000
Self-insurance accruals	3,286,000	3,624,000
Other	1,088,000	1,162,000
	<u>\$13,758,000</u>	<u>\$11,847,000</u>

Note D — Income Taxes

The income tax provision consists of the following for the three years ended March 31:

	2002	2003	2004
Current — Federal	\$8,226,000	\$ 8,255,000	\$7,548,000
Current — State	897,000	910,000	482,000
Subtotal	9,123,000	9,165,000	8,030,000
Deferred — Federal	(36,000)	900,000	1,208,000
Deferred — State	(4,000)	99,000	115,000
Subtotal	(40,000)	999,000	1,323,000
	<u>\$9,083,000</u>	<u>\$10,164,000</u>	<u>\$9,353,000</u>

Income tax benefits associated with the exercise of stock options are excluded from the provision, credited directly to equity, and totaled \$606,000, \$1,265,000 and \$2,035,000 for fiscal 2002, 2003, and 2004, respectively.

The following is a reconciliation of the income tax provision from the statutory federal income tax rate to the effective rate for the three years ended March 31:

	2002	2003	2004
Income taxes at federal statutory rate	\$8,336,000	\$ 9,362,000	\$8,878,000
State income taxes, net of federal benefit	893,000	1,008,000	809,000
Other	(146,000)	(206,000)	(334,000)
	<u>\$9,083,000</u>	<u>\$10,164,000</u>	<u>\$9,353,000</u>

CORVEL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Income taxes paid totaled \$7,910,000, \$8,812,000 and \$6,455,000 for the years ended March 31, 2002, 2003, and 2004, respectively.

Deferred taxes at March 31, 2003 and 2004 are:

	<u>2003</u>	<u>2004</u>
<i>Deferred tax assets:</i>		
Accrued liabilities not currently deductible	\$ 3,864,000	\$ 2,985,000
Allowance for doubtful accounts	1,163,000	1,319,000
Other	<u>2,000</u>	<u>12,000</u>
Deferred assets	5,029,000	4,316,000
<i>Deferred tax liabilities:</i>		
Excess of book over tax basis of fixed assets	(4,920,000)	(5,363,000)
Other	<u>(547,000)</u>	<u>(714,000)</u>
Deferred liability	<u>(5,467,000)</u>	<u>(6,077,000)</u>
Net deferred tax liability	<u>\$ 438,000</u>	<u>\$ 1,761,000</u>

Prepaid expenses and taxes includes \$2,915,000 and \$2,462,000 at March 31, 2003 and March 31, 2004, respectively, for income taxes due in the first quarter of the succeeding fiscal year.

Note E — Stock Options

Under the Company's Restated 1988 Executive Stock Option Plan, ("the Plan") as amended, options for up to 5,955,000 shares (adjusted for the two-for-one stock split in the form of a dividend in May 1999 and the three-for-two stock split in the form of the dividend in August 2001) of the Company's common stock may be granted to key employees, non-employee directors and consultants at prices not less than 85% of the fair value of the stock at the date of grant as determined by the Board. Options granted under the Plan may be either incentive stock options or non-statutory stock options and options granted generally have a maximum life of five years.

CORVEL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Summarized information for all stock options for the past three fiscal year follows:

	2002	2003	2004
Options outstanding at the beginning of the year	1,104,994	1,218,088	1,197,747
Options granted	278,702	198,600	138,871
Options exercised	(146,988)	(204,955)	(277,240)
Options forfeited	(18,620)	(13,986)	(64,903)
Options outstanding at the end of the year ...	<u>1,218,088</u>	<u>1,197,747</u>	<u>994,475</u>
During the year, weighted average price of options:			
Granted	\$ 26.82	\$ 32.63	\$ 34.63
Exercised	\$ 10.88	\$ 12.24	\$ 13.55
Forfeited	\$ 16.23	\$ 22.37	\$ 14.75
At the end of the year:			
Price range of outstanding options	\$5.67 - \$30.55	\$5.67 - \$33.91	\$6.13 - \$38.74
Weighted average price per share	\$ 16.86	\$ 20.20	\$ 24.42
Options available for future grants	990,317	805,703	731,735
Exercisable options	587,803	634,493	585,529

The following table summarizes the status of stock options outstanding and exercisable at March 31, 2004:

Range of Exercise Prices	Number of Outstanding Options	Weighted Average Remaining Contractual Life	Outstanding Options — Weighted Average Exercise Price	Exercisable Options — Number of Exercisable Options	Exercisable Options — Weighted Average Exercise Price
\$ 6.13 - \$15.75	201,115	1.90 years	\$12.72	187,165	\$13.01
17.50 - 23.17	221,029	1.86 years	19.05	186,685	18.89
24.20 - 30.55	297,161	3.21 years	27.34	162,776	26.90
31.24 - 38.74	<u>275,170</u>	<u>4.55 years</u>	<u>34.13</u>	<u>48,903</u>	<u>33.67</u>
Total	<u>994,475</u>	<u>3.01 years</u>	<u>\$24.42</u>	<u>585,529</u>	<u>\$20.47</u>

The weighted average fair values at date of grant for options granted during fiscal 2002, 2003, and 2004 were \$6.38, \$7.77, and \$9.77, respectively.

The fair value of each grant is estimated on the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were used for fiscal years ending March 31:

	2002	2003	2004
Expected volatility28	.30	.33
Risk free interest rate	4.3%	2.4%	3.9%
Dividend yield	0.0%	0.0%	0.0%
Weighted average option life	4.6 years	4.6 years	4.6 years

CORVEL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The number of shares to be issued, the weighted average exercise price of outstanding options, and the number of securities remaining available for future issuance under all stock option plans, including the 1991 Employee Stock Purchase Plan described in Note F below are as follows:

<u>Plan Category</u>	<u>Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants, and Rights</u>	<u>Weighted-average Exercise Price of Outstanding Options, Warrants and Rights</u>	<u>Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans</u>
Equity compensation plans approved by security holders	994,475	\$24.42	814,885
Equity compensation plans not approved by security holders	<u>—</u>	<u>—</u>	<u>—</u>
Total	<u>994,475</u>	<u>\$24.42</u>	<u>814,885</u>

Note F — Employee Stock Purchase Plan

The Company maintains an Employee Stock Purchase Plan which allows employees of the Company and its subsidiaries to purchase shares of common stock on the last day of two six-month purchase periods (i.e. March 31 and September 30) at a purchase price which is 85% of the closing sale price of shares as quoted on NASDAQ on the first or last day of such purchase period, whichever is lower. Employees are allowed to participate up to 20% of their gross pay. A maximum of 750,000 shares has been authorized for issuance under the plan, as amended. As of March 31, 2004, 666,850 shares had been issued pursuant to the plan. Summarized plan information is as follows:

	<u>2002</u>	<u>2003</u>	<u>2004</u>
Employee contributions	\$788,000	\$952,000	\$1,143,000
Shares acquired	36,951	37,147	39,295
Average purchase price	\$ 21.32	\$ 25.63	\$ 29.09

Note G — Treasury Stock

During fiscal 2004, the Company continued to repurchase shares of its common stock under a plan approved by the Company's Board of Directors. Including an expansion authorized in April 2002, the total number of shares authorized to be repurchased has now been increased to 6,100,000 shares. Purchases may be made from time to time depending on market conditions and other relevant factors. The share repurchases for fiscal years ending March 31, 2002, 2003 and 2004 are as follows:

	<u>2002</u>	<u>2003</u>	<u>2004</u>	<u>Cumulative</u>
Shares repurchased	557,870	461,527	342,121	5,573,428
Cost	\$15,237,000	\$14,987,000	\$12,154,000	\$96,281,000
Average price	\$ 27.31	\$ 32.47	\$ 35.53	\$ 17.28

The repurchased shares were recorded as treasury stock, at cost, and are available for general corporate purposes. The repurchases were financed from cash generated from operations.

Note H — Commitments and Contingencies

The Company leases office facilities under noncancelable operating leases. Future minimum rental commitments under operating leases at March 31, 2004 are \$9,803,000 in fiscal 2005, \$8,891,000 in fiscal 2006, \$7,616,000 in fiscal 2007, \$5,695,000 in fiscal 2008, \$1,898,000 in fiscal 2009, and \$359,000 thereafter.

CORVEL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Total rental expense of \$9,926,000, \$10,368,000 and \$11,365,000 was charged to operations for the years ended March 31, 2002, 2003, and 2004, respectively.

The Company is involved in litigation arising in the normal course of business. The Company believes that resolution of these matters will not result in any payment that, in the aggregate, would be material to the financial position or results of the operations of the Company.

Note I — Savings Plan

The Company maintains a retirement savings plan for its employees, which is a qualified plan under Section 401(k) of the Internal Revenue Code. Full-time employees that meet certain requirements are eligible to participate in the plan. Contributions are made annually, primarily at the discretion of the Company's Board of Directors. Contributions of \$247,000, \$283,000 and \$150,000 were charged to operations for the years ended March 31, 2002, 2003 and 2004, respectively.

Note J — Business Combinations

In May 2002, the Company acquired the assets of AnciCare, PPO, Inc., a Florida-based national provider of diagnostic imaging services. The Company paid approximately \$3.4 million (\$2.9 million during fiscal 2003 and \$475,000 during fiscal 2004) and recorded approximately \$3.3 million for goodwill. If the results of the AnciCare operations attain certain revenue during each of the three years after the date of acquisition, the Company will pay an additional amount for the purchase, which is expected to be funded from future earnings of the Company. Any additional amounts paid will increase the goodwill related to the acquisition. No amounts were paid for attaining certain revenue targets for each of the first two years after the date of the acquisition.

The following table summarizes the recorded value of the AnciCare assets acquired and liabilities assumed at the date of acquisition:

Accounts receivable, net	\$3,039,000
Property and equipment, net	297,000
Prepaid expenses	93,000
Goodwill	<u>3,302,000</u>
Subtotal	<u>6,731,000</u>
Less: Accounts payable and other current liabilities	<u>3,243,000</u>
Net Assets	<u>\$3,488,000</u>

In June 2003, the Company acquired 100% of the stock of Scan One, a document imaging company which is being integrated in the Company's network solutions operations. The Company paid \$3.7 million for the stock and to repay certain outstanding obligations of Scan One and recorded \$3.2 million of goodwill. There are no contingent obligations in the price for this acquisition.

CORVEL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following table summarizes the recorded value of the Scan One assets acquired and liabilities assumed at the date of acquisition:

Accounts receivable, net	\$ 303,000
Property and equipment, net	375,000
Prepaid expenses	136,000
Goodwill	<u>3,219,000</u>
Subtotal	<u>4,033,000</u>
Less: Accounts payable and other current liabilities	<u>280,000</u>
Net Assets	<u>\$3,753,000</u>

The following unaudited pro forma summary presents information as if AnciCare and Scan One had been acquired as of the beginning of the periods presented. The pro forma information does not necessarily reflect the actual results that would have occurred nor is it necessarily indicative of future results of operations of the combined companies.

	<u>2002</u>	<u>2003</u>	<u>2004</u>
Pro forma revenue	\$253,312,000	\$287,676,000	\$305,979,000
Pro forma net income	\$ 14,911,000	\$ 16,755,000	\$ 16,034,000

Note K — Shareholder Rights Plan

During fiscal 1997, the Company's Board of Directors approved the adoption of a Shareholder Rights Plan. The Rights Plan, which is similar to rights plans adopted by numerous other public companies, provides for a dividend distribution to CorVel stockholders of one preferred stock purchase "Right" for each outstanding share of CorVel's common stock. The Rights are designed to assure that all stockholders receive fair and equal treatment in the event of any proposed takeover of the company and to encourage a potential acquirer to negotiate with the Board of Directors prior to attempting a takeover. In April 2002, the Board of Directors of the Company approved an amendment to the Company's existing stockholder rights agreement to extend the expiration date of the rights to February 10, 2012, increase the initial exercise price of each right to \$118, and enable Fidelity Management & Research Company and its affiliates to purchase up to 18% of the shares of common stock of the Company without triggering the stockholder rights. The Rights will not be exercisable until the occurrence of certain takeover-related events. The issuance of the Rights has no dilutive effect on the Company's earnings per share.

Note L — Line of Credit

In April 2003, the Company entered into a credit agreement with a financial institution to provide borrowing capacity of up to \$5 million. This agreement expires in September 2004. Borrowings under this agreement bear interest, at the Company's option, at a fluctuating LIBOR-based rate plus 1.25% or at the financial institution's prime lending rate. There were no borrowings under the line of credit at March 31, 2003 or March 31, 2004. The loan covenants require the Company to maintain a quick ratio of at least 2:1, a tangible net equity of at least \$45 million, and have positive net income. The Company was in compliance with these covenants at March 31, 2004.

CORVEL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Note M — Quarterly Results (Unaudited)

The following is a summary of unaudited results of operations for the two years ended March 31, 2003 and 2004:

	<u>Revenues</u>	<u>Gross Margin</u>	<u>Net Income</u>	<u>Net Income per Basic Common Share</u>	<u>Net Income per Diluted Common Share</u>
Fiscal Year Ended March 31, 2003:					
First Quarter	\$66,301,000	\$12,310,000	\$4,029,000	\$.37	\$.36
Second Quarter	69,353,000	13,332,000	4,091,000	.38	.37
Third Quarter	73,135,000	13,023,000	4,193,000	.39	.38
Fourth Quarter	73,987,000	13,164,000	4,271,000	.40	.39
Fiscal Year Ended March 31, 2004:					
First Quarter	\$75,912,000	\$13,608,000	\$4,357,000	\$.41	\$.40
Second Quarter	76,978,000	13,430,000	4,458,000	.42	.41
Third Quarter	75,631,000	12,638,000	4,082,000	.38	.38
Fourth Quarter	76,758,000	11,757,000	3,116,000	.29	.29

(This page intentionally left blank)

Board of Directors

Gordon Clemons
Chairman

Steven J. Hamerslag
Director

Alan R. Hoops
Director

Judd Jessup
Director

Jeffrey J. Michael
Director

Corporate Officers

Tom Benson
VP, Information Systems

Gordon Clemons
Chairman, President and CEO

Peter E. Flynn
VP, Business Development

Don McFarlane
VP, Information Technology

Sharon O'Connor
Director, Legal and Human Resources

Richard Schweppe
Chief Financial Officer and Secretary

Corporate Address

CorVel Corporation
2010 Main Street
Suite 600
Irvine, California 92614

Telephone: 888 7 CORVEL

Transfer Agent and Registrar

U.S. Stock Transfer Corporation
Glendale, California

Counsel

Dorsey & Whitney, LLP
Irvine, California

Independent Auditors

Grant Thornton LLP
Portland, Oregon

Stock Symbol

The common stock of CorVel Corporation is traded on the NASDAQ National Market System under the stock symbol CRVL.

Form 10K

CorVel Corporation Annual Report on Form 10K filed with the Securities and Exchange Commission may be obtained without charge by contacting:

Investor Relations

CorVel Corporation
2010 Main Street
Suite 600
Irvine, California 92614

Telephone: 888 7 CORVEL
www.corvel.com/ar2004
e-mail: investor_relations@corvel.com

CORVEL



Insight. In Touch.



W. Kim

3,000
Associates

1,500 customers

160
Offices


Insight. In Touch. CorVel Corporation is a national provider of leading edge managed healthcare solutions to employers, third party administrators, insurance companies and government agencies. CorVel specializes in applying advanced communication and information technology to improve healthcare management in the workers' compensation, group health and auto insurance markets. Our 3,000 associates in 160 offices nationwide work side by side with our customers to deliver innovative, tailored solutions to manage risk.

What CorVel knows can make healthcare management, manageable.

CorVel ensures that companies see the right information at the right time.

Because for our customers, *when* they know is as important as *what* they know.





What CorVel sees is the big picture through details,

preventing small things from becoming big things.




Auto

Workers

Markets


Group
Health

Insight. CorVel specializes in applying advanced communication and information technology to improve healthcare management in the workers' comp, group health and auto insurance markets.

A high-contrast, black and white photograph. In the foreground, a hand is holding a pen, with the pen tip pointing towards the left. The hand and pen are silhouetted against a bright, overexposed background. In the background, a document is visible, showing some text and a circular logo. The overall image has a grainy, high-contrast aesthetic.

We make sure the right care is delivered, and that it's delivered efficiently,

with experienced professionals involved with customers and patients at every step.



Expertise Within Reach. CorFirst is the first solution that utilizes proprietary technology to identify and prioritize claims. CorCase is CorVel's suite of case management solutions. Our 1,200 case managers work side by side with patients to assist them through their episode of care and return to work.




We offer the power of a national solution – delivered locally.


It's a combination of strength and personal attention that no one else can match.




Network Solutions



Managing Risk: CorVel provides choice and access for patients and payors through its CorCare network of more than 500,000 preferred providers and through CorCheck, CorVel's proprietary bill review and network management technology.



In Touch. Care™ provides real time claims data and knowledge online, to be accessed whenever and wherever it's needed. Care™'s advanced proprietary technology consolidates information to expedite resolutions and improve outcomes.



What CorVel offers is insight from innovative technologies that are in touch
with the needs of our customers, their employees, and communities...

...bringing resolution to a complex process.

"As we enter fiscal 2005, the Company is adding to the breath of its product

line and continuing its investment in innovation.

The markets served by CorVel are undergoing change as well."



In CorVel's fiscal 2004, a soft claims market, legislative changes in two states and our delayed response to these changes, combined to create a year of transition. At this time, we are working on both the response to these new conditions and our plans to deliver an expanded product line in the future. As we enter fiscal 2005, the Company is adding to the breadth of its product line and continuing its investment in innovation. The markets served by CorVel are undergoing change as well. Healthcare insurance is increasingly becoming a transaction processing industry, with automation increasing each year.

Just as the commercial banking industry automated its transaction processing, today's healthcare insurers must compete with much increased efficiency and speed. CorVel's existing position in the review and processing of healthcare transactions positions the Company to be a leader in the changes coming to this market. During the year we added to our ability to process transactions electronically, as well as our ability to scan and process the paper that still dominates the workers' compensation marketplace. Our long term investment in Care^{MC}, CorVel's transaction processing website, continues to position us to participate in the ongoing expansion in the automation employed in our markets.

During the year the addition of a large number of customers to our newest software caused a slowdown in processing speeds. "Scalability" has always been a concern for any company selling technology. That is, can software operating well at one level of activity, perform equally well at a larger scale. Both our software development and systems operations staff put in extensive hours and endless days under the constant pressure of customer service requirements. Their efforts and talent quickly returned processing speeds to normal and paved the way to further expansions of capacity.

Although last year was a challenge, our organization was productive. A key ingredient in our success over the years has been a large, core group of people. By staying together in both the good times and the difficult years, these people have built CorVel over a fifteen year period. The size of our Company, and our ever more visible role in healthcare, attracts talented people. This next generation in our organization brings new talents, new visions. We are more vibrant than at any time in our past.

Throughout the year we added new data center facilities, expanded analytic capabilities and moved most of our legacy processing to new software. The wisdom

of prior years' investments in accounting and enterprise management software became more evident as recent legislation expanded the requirement for internal business controls.

Artificial intelligence, scanning, rules engines, the internet, new processors and storage networks. Innovation. New services. New markets and new positions in our current markets. While these sound like the building blocks of CorVel's future, in lieu of internal development, all can be purchased. But in the end, people make the difference. The CorVel difference is that we have been together through all of this. And remain together as we define the best paths forward.

The combination of our veterans and next generation of product developers has been critical to CorVel's expanding use of artificial intelligence. Automated processing is becoming a part of an ever increasing portion of CorVel applications. "Rules engines" have added consistency and sophistication to processing. Taking full and proper advantage of this power remained an unfinished project during the year. The performance of these tools has exceeded our expectations.

Building an effective position within the complex world of healthcare financing

requires penetrating intellectual skills and a steady persistence.

There is still work to be done to have the power of our applications be appropriately appreciated by current and prospective customers. Also, as is often the case with evolving technology, future possibilities do not become sufficiently clear until after we reach the next plateau in development. We find that as we reach a higher level of technology and performance, we usually see subsequent opportunities.

Our organization's longevity is the foundation for our ongoing progress. In challenging times we depend upon their commitment and determination. In the best of times we share their joys. Always, we are thrilled by their humanity and talents. The Company's long term success is the visible evidence of our team's collective accomplishments. Building an effective position within the complex world of healthcare financing and transaction processing requires both penetrating intellectual skills and a steady persistence.

A handwritten signature in black ink, appearing to be "J. L. Smith", is located in the bottom right corner of the page. The signature is fluid and cursive, with a large initial "J" and "L".

Our team's longevity is the foundation for our ongoing success.

Janet Aalto-Reno	Andrew Babbitt	Jerriett Bennett	Susan Breitenberg	Sandra Carney	Carol Colliandra
Melody Abarca	April Baca	Makia Benniefield	Christy Brewer	Mendy Carpenter	Carlethia Collier
Nicole Abdallah	Brandi Baca	Dena Bennight	Kelly Brewer	Jeanna Carr	Kristi Collier
Andrew Abela	Billie Bacon	Michelle Bennight	Mary Brewer	Jeraldine Carreras	Trisha Collings
Robin Accio	Jeffrey Acer	Maryanne Benninger	Dalyn Carrier	Dalyn Carrier	Edward Collins
Kendra Ackerman	Marilyn Bahret	Kathleen Bennington	Susan Brewer	Alina Carrillo	Jennifer Collins
Sandra Acosta-Delgado	Altah Bailey	Charles Benson	Beverly Brezski	Yariela Carrizo	Michelle Collins
Gini Adams-Cannon	Georgia Bailey	Thomas Benson	Jill Brice	Amy Carroll	Sharon Collins
Carla Adams	Jennifer Baillargeon	Debra Benyounes	Stephanie Bridges	Jonathan Carroll	Meissa Colon
Cindy Adams	Danielle Baker	Eleanor Berdous	Debra Brim	Marise Carroll	Sebreia Colquitt
Glen Adams	Dena Baker	Robert Beres	Donna Briscoe	Carla Carron	Sharlene Coma
Glenda Adams	Jacqueline Baker	Tamara Berger	Anne Brito	Courtney Carron	Michael Combs
Patricia Adams	Kathleen Baker	Jeffrey Bergerin	Katherine Britton	Jeffrey Carter	Renee Concolino
Linda Baker	Maggie Baker	Mary Ann Berhow	Linda Carter	Patricia Broad	Thomas Conley
Patricia D. Adams	Stephen Baker	Jack Berman	Peta Gaye Carter	Lizette Casanova	Kristy Conn
Shannon Adams	Teresa Baker	Mollie Bernstein	Deborah Brock	Linda Cash	Jo-Ann Connelly
Cathy Aden	Yonna Baker	Judy Berrios	Jeffrey Brock	Cathy Cassi	Joyce Conner
Fred Adge	Adrian Bala	Katherine Berry	Elizabeth Brockovich	Lanette Cassel	Patricia Conner
Maribel Adorno Diaz	Barry Baldwin	Anne Berson	Judith Brodal	Amy Cassell	Stephen Conner
Vijay Agrawal	Sharon Baldwin	Mark Bertels	Seth Brody	Rebecca Cassidy	Christine Conquest
Angie Aguayo	Carolyn Ballard	Gail Berube	Bettie Broisma	Kirsten Castagnoli	Chyra Conrad
Donna Aguilar	Clydetta Baltimore	Mariana Betancourt	Lee Brooke	Joanne Castell	Julie Conrad
Anne Aiello	Donna Balzer	Michael Bethel	Monica Brooker	Marjorie Castillo	Karen Conroy
Heather Aitrop	Sonia Barbino	Michelle Betz	Melanie Brooks	Mayra Castillo	Patricia Conzolo
Natalia Akridge	Terrie Banas	Vicki Betz	Shannon Brophy	Martin Castro	Justin Conte
Leah Alcorn	Mary Beth Bania	Tamera Beverly	Arthur Brouillette	Christine Brown	Connie Conway
Rachel Alden	Mathis Banks Jr.	Rebecca Bianchi	Christine Brown	Harold Caudell	Angela Cook
Helen Alexander	Eric Banks	Daryl Bianco	Martha Brown	Kristin Cava	Danielle Cook
Maria Alexander	Gail Banks	April Bicoy	Maureen Brown	James Cavallo	Darren Cook
Theresa Alexander	Kimberly Banks	Shawna Biegel	Melissa Brown	Lisa Ceccolini	Cynthia Cooke
Virginia Alford	Marcella Banks	Jennifer Bierly	Rod Brown	Miguel Cedenio	Patricia Cooley
Ellen Alldredge	Carla Bankston	Duane Bigelow	Walisa Brown	Nathan Centeno	Frank Cooney
Dana Allen	Linda Hepburn	Kerry Biggs	Sherry Browning	Marie Cepeda	Elaine Cooper
Jane Allen	James Barbarise	Cynthia Bilis	Betty Bruce	Pamela Cerny	Tracy Cooper
Michael Allen	Jan Barчук	Connie Binder	Charles Cerpa	Barbara Cervantes	Laurel Coover
Rhonda Allen	Dwight Bardot	Daniel Bine	April Bryant	Lupita Cervantez	Irene Coppola
Mike Almquist	Lilia Barias	Lilly Binns	Allyson Buck	Deanna Cessna	Christine Corbett
Brian Alci	Brandon Baricuatro	Muhiba Birashk	Marysheila Buckley	Sonya Chacon	Ana Cordero
Felisa Alonzo	Melinda Baricuatro	Shahira Birashk	Diane Buckner	Paula Chalpin	Christina Cordero
Katheryn Altenhofen	iona Barin	Genea Birmingham	Susan Budden	Vickie Chaltas	Elizabeth Corey
Karl Altman	Srenda Barker	Amy Biron	Edgardo Buenaobra	Tacy Chambers	Shavon Cormick
Chona Alvarez	Priscilla Barker	James Bischel	Kathy Buenger	James Chambers-Welch	Amy Cormier
Phil Amadio	Velda Barlatier	Karen Buffington	Karen Buffington	Chanthoeun Chan	Petra Cornell
Charis Amador	Kimberly Barner	Judith Bukoski	Julie Bumgarner	Lucy Chan	Debbie Correa
Sonya Amaker	Karen Barnes	Hallie Bissett	Amparo Buono	Sarot Chan	Ian Corson
Elaine Amber	Michelle Barnes	Daniel Bitar	Phyllis Burgess	Denise Chandler	Jaime Coshow
Debra Ambroff	Monica Barnes	Linda Bittner	Michael Burnett	Kristina Chandler	Karen Costa
Mary Jo Andersen	Rebecca Barnes	Ann Bitter	Judy Burney	Lori Chandler	Michael Costello
Angela Anderson	Shumeki Barnett	Brian Black	Heather Burnham	Ya-Ding Chang	Raquel Cotto
Barbara Anderson	Margaret Barrney	Jessica Blackwood	Cecelia Burrus	Jeri Chapman	Susan Cotto
Candice Anderson	Matthew Barnhart	Diane Blaha	Diane Burton	John Chapman	Karen Coulis
Cheryl Anderson	Deana Collins	Marcia Blair	Jennifer Burton	Jocelyn Charles	Linda Coulton
Heather Anderson	Patti Barovechio	Todd Blaisdell	Andre Bush	Linda Charlton	Sara Courts
Jodi Anderson	Tanya Barrans	Linda Blake	Ladonna Bush	Terri Charney	Johanna Cousineau
Leslie Anderson	Ses Barretas	Delecia Blalock	Linda Bushrod	Nathan Chaskin	Clinton Cowington
Rowena Anderson	Karen Barrett	Elizabeth Bianco	Nora Buslik	Jeffrey Chastain	Ashley Cox
Sara Jane Anderson	Donna Barringer	Judy Blankenship	Lydia Bustillo	Theresa Chausse	Daniel Cox
Sharon Anderson	Margaret Barrins	Leslie Blanyer	Debbie Button	Darunwan Chayabutr	Frank Cox
Dennis Andrade	Darrell Barton	Rebekkah Blashka	Reta Butts	Malisha Cheatham	Gloria Cox
Jane Andrews	Soledad Barron	Sarah Blakey	Lori Byrd	Christina Cheek	Gregor Cox
Jeannette Andrews	Gwyn Barry	Dianne Blum	Renee Byrd	Gwen Spence	Laurie Cox
Ronnie Andrews	Terryann Barry	Jan Blumenthal	Carol Byrnes	Yvonne Chen	William Cox
Carla Anguiano	Susan Bartlett	Mary Beth Bocksel	Karen Byrns	Marcia Cheney	Karen Craik
Judy Anti	Jackie Bartley	Christine Bode	Lisa Cabral	Que Cheng	Sherry Cramer
Madeline Antuna	Jill Bartling	Martin Bohm	Catherine Cafferty	Elizabeth Chernisky	Suzanne Crane
Lee Anzaldi	Glenda Barton	William Bohm	Catherine Cain	Mary Ann Chestnut	Nancy Creech
Salvatore Apodaca	Legoria Barton	Christine Boike	Marian Cajanding	Nancy Chettle	Janet Creeger
Tamara Aponte	Bonnie Bartosh	Mary Lynn Boline	Myrtle Calbert	Mikael Childers	Rachel Creese
Daniel Aragon	Brian Bartunek	Guayilla Boller	Suzanne Calbeck	Amanda Chiong	Sara Crew
Michelle Aragon	Ruth Bartunek	Stacey Bolton	Steve Caldwell	Debbie Chmielorski	Te miya Crockett
Helen Arce	Linda Bass	Kaylee Bond	Carole Calhoun	Haewon Choi	Monica Cronin
Andres Ardila	Christine Bateman	Theresa Bone	Al Caliguri	Sandra Christian	Sherray Croskey
Aimee Ardoin	Amanda Bates	Tina Booker	Anne Callahan	Dawn Christianson	Derek Cross
Barbara Arduino	Susan Bates	Mary Booth	Joseph Caminiti	Jennifer Churchill	Robert Crouch
Desiree Arielano	Torrey Bates	Ann Bordaeanu	Bruce Campbell	Donna Chung	Pamela Cruce
Kathy Arens	Kellie Batista	Joseph Borgerding	Deb Campbell	Alice Church	Monica Crumley
Ivonne Arias	Swanetta Battles	Wawa Borgerding	Donna Campbell	Gretchen Church	Ida May Cubitt
Crawford Armstrong	Dustin Baughman	Phillip Borgman	Mary Campbell	Karen Cichocki	Laura Cuddihy
Janeen Armstrong	Lawrence Baughn	Maria Bosko	Elizabeth Campbell	Alejandra Cisneros	Fernando Cuevas
Karen Arndt	Erlinda Baula	Suzanne Bouchard	Michelle Campion	Candace Clark	Mary Ann Cullen
Teresa Arnold	Kathleen Baumes	Bonnie Boucher	Delmi Canales	Holly Clark	Bobbie Culley
Elizabeth Arnsdorff	Barbara Bavery	Peggy Bowden	Michelle Campisi	Karrie Clark	Dana Culpepper
Patricia Aronin	Denys Beach	Michelle Bower	Javier Canales	Thomas Clark	Stephen Culver
Angela Arrowood	Sandra Beard	Katherine Bowers	Rosemary Canitia	Janet Clarke	Katharine Cummings
Amanda Arthur	Barbara Beardsley	Wanda Bowers	Neil Cannon	Amiete Clement	Donna Cunningham
Roxanna Artica	Evelyn Beasley	Geary Bowling	Suzanne Cannon	Gordon Clemons	Joseph Cunningham
Bennie Artis	Jessica Beaudis	Julie Boyd	Michael Cantow	V. Gordon Clemons	Linda Cunningham
Vivian Arzola	Cynthia Becher	Joan Beck	Katherine Cantrell	Elizabeth Cleves	Michelle Cunningham
Brian Asbill	Mark Beck	Philip Beers	Lowyn Cantrell	John Cleves	Kathleen Curran
Evelyn Asendo	Kimberly Beesley	Debra Behrik	Tony Cao	Susan Ciewell	Brian Cusard
Ernest Attewell	James Beisheim	Patricia Belcarz	Deb Cappello	Josh Cliburn	Brenda Custer
Chris Auger	Teresa Belew	Kimberly Bell	Jennifer Marie Capps	Teresa Clift	Marianne Cuthbertson
Daedra Ault	Kimberly Bell	Lori R Brackett	Brandy Caraballo	Vivianne Clifford	Robyn Cutsail
Denise Ellen Ault	Latoria Bell	Moirne Bradburn	Fawn Caroff	Elizabeth Cline	Jennifer Czarniecki
Myrna Austin	Pennie Belott	Angela Braddock	Maikel Cardente	Lois Cline	Julie Czerniak
Kristie Averitt	Christine Belrose	Anita Bradford	Joyce Carlen	Diane Clinton	Catlin Czerwinski
Defia Avila	Steven Benjamin	Robbie Brainard	Shelley Carlen	Erin Cloos	Jennifer D'Agostino
Benigno Ayala	Jennifer Bennett	Tommy Brainard	Anita Carleton	Steven Cochran	Donna Danlstrom
Sherri Ayers		Pamela Brakhage	Lynne Carleton	Lori Cochran	Peggy Daily
Shelley Ayres		Rose Brandt	Elaine Carlson	Denise Coleman	Jodi Daly
Shannon Babb		Pamela Braxwell	Jeffrey Carlson	Helen Coleman	Mary Daly
		Brenda Bratumil	Susan Carlson	Javon Coleman	Debra Dambacher
		Jennifer Breaker	Beverly Cariton	Regina Coleman	Edith Damico
		James Breen	Donna Carlton	Alida Cole	Susan Damron
			Jewelle Carnegie	Carol Ann Colgan	Brandi Daniel
					Robert Daniel

Darron Daniels	Cheryl Ducharme	Sally Ferguson	Kenneth Gaddis	Nancy Graham	Randall Harding
Dixie Daniels	Linda Duckworth	Tracy Ferguson	James Gadow	Carlyle Grant	Natalie Hardy
Diane Danis	Sharon Dufek	Janet Fernandez	Anthony Gage	Linda Grant	Donna Haring
Shawna Daras	Matthew Duffin	Maria Fernandez-Barona	Dawn Galde	Ronald Grant	James Harlan
Kathleen Darhun	Robert Dufur	Nicole Ferrara	Dianne Gaines	Jacqueline Grass	Tara Harlan
William Darmon	Christin Duhl	Marilyn Ferringer	Connelita Gaither	Beth Graves	Lynn Harmening
Kimberly Darnstaedt	Milanka Dukic	Kimberly Ferris	Sara Gall	Janet Graves	Lynn Harner
Elizabeth Dasko	Kimberly Dunafon	Maria Ferry	Judith Gallagher	Marilyn Gravgaard	Julia Harper
Carlotta Daugherty	Christine Duncan	Araceli Fierros	Sarita Gallagher	Kathleen Gray	Suzan Harper
Susan Daugherty	Marilynn Duncan	Carla Gallamore	Carla Gallamore	Marcia Gray	Doris Harrah
Christie Davenport	Jennifer Duncan-Garrett	Susan Galyo	Mary Jane Gray	Greta Graydon	Cecelia Harrell
Luann Davenport	Kathleen Duncanson	Regina Gann	Mary Grayson	Tasha Greaves	Diane Harrell
Tina Davenport	Jerald Dunlap	Cheryl Gannon	Margaret Grecula	Margaret Grecula	Amanda Harris
Anita Davidson	Katherine Dunlap	Patrick Gannon	Arlene Green	Charles Green	Carmen Harris
Anthony Davis	Lori Dunnire	Angie Garber	Katia Green	Michelle Green	James Harris
Dottie Davis	Deanna Dunn	Amanda Garcia	Christina Garcia	Rubén Harris	Lana Harris
James Davis	Karyn Dunn	Beth Fisher	Julia Garcia	Ilse Greer	Mary Harris
Judy Davis	Jayna Dunning	Karen Fisk	Mamie Garcia	Veronica Gregg	Patricia Harris
Kathy Davis	Leslie Dunn-Kiniry	Kathleen Fitzgerald	Maria Garcia	Jennifer Greminger	Rosabel Harris
Misty Davis	Almee Duque-Randolph	Rebecca Fitzgerald	Michael Garcia	Jamie Gribben	Sandra Harris
Tracey Davis	Jeanette Duschka	Sherry Fitzgerald	Stephanie Garcia	Salina Griego	Katherine Harl
Yvette Davis	Jacqueline Earsley	Mike Flacco	Stephen Gardner	Charlotte Griffin	Jean Hartman
Dianne Dawkins	Lenore Eason	Oona Flaherty	Robin Garhartt	James Griffin	Mari Hartman
James Dawson	Dejuane Eastland	Nancy Eckl	Erica Garibay	Joanne Griffin	Diane Hartrick
Stephen Dean	Sandra Eblright	Peter Edgerton	Sara Garner	Nikki Griffin	Karen Hartwell
Catherine Dechene	Penny Ecaruan	Helena Edmondson	Doreta Garnett	Linda Griffith	Robert Harvan
Andrea Dechter	Nancy Eckl	Carol Edwards	Catherine Garrett	Steve Griffiths	Beth Harvey
Rita Dedominic	Peter Edgerton	Charlotte Edwards	Cynthia Garrett	Ludie Grigsby	Harriet Harvey
Teresa Dee	Helena Edmondson	Linda Edwards	Shirlyn Garrett	Denise Grijalva	Marci Harvey
Connie DeFilippo	Maryann Edwards	Dion Edwards	Deborah Garris	Elena Grijalva	Mary Hasenstaub
Roberta Degeer	Carol Edwards	Melinda Edwards	Heather Garrison	Claude Grise	Kenneth Haskins
Kathleen Degroot	Charlotte Edwards	Nakia Westbrooks	Mary Louise Gartland	Leslie Groce	Lavon Hasselbring
Letty Deguzman	Linda Edwards	Tena Floyd	Carol Gasser	Karen Gronberg	Stephanie Haston
Kathleen Deimling	Maryann Edwards	Carole Fluegel	Shelie Gronlund	Johnathan Gronsdahl	Milton Hasty
Karleen Dejean	Dion Edwards	Donna Flynn	Johnathan Gronsdahl	Amie Gross	Faye Hatch
Miguel DeJesus	Sophia Edwards	Peter Flynn	Vladimir Gaytanov	Deborah Gross	Nicole Hawthorne
Monica DeJesus	Theresa Edwards	Robin Egan	Robin Gebreyesus	Kelly Grossman	Debra Haugen
Rhodora Del Castillo	Vanessa Edwards	William Egan	Andee Gedman	Amanda Grove	Janel Haw
Evan Delaney	Luann Esley	Connie Ehlers	Samantha Gehrmann	Luane Grube	Vivien Hawe
Karen Delavan	Robin Egan	Alan Eller	Deborah George	Patricia Gruenewald	Carla Hawley
Carmenita DeLeon	William Egan	Patricia Eisele	Mary George	Philip Grupp	Eileen Haworth
Brandon Delgado	Connie Ehlers	Rachel Eliason	Patricia George	Elizabeth Guerrero	Scott Hayden
Jillian Delia	Alan Eller	Shannon Elkin	Maria Georgiandis	Carol Guertin	Albertine Hayes
Shirley Delorme	Patricia Eisele	Traci Ellefson	Diane Geraci	Sharon Guevarra	Janet Hays
Paula Deluca	Thomas Eix	Peggy Ellerbusch	Terri Gerichs	Nicole Guilbert	Tamera Hazeltine
Paul DeMordaunt	Rachel Elliot	Rachel Elliot	Paula Gerry	Katherine Guillano	Patricia Heater
Sharon Dempsey	Robert Elliott	Beverly Ellis	Patricia Gertz	Alice Guillen	Diana Heathcote
Jill Dempsey	Cynthia Ellis	Melissa Ellis	Brian Gesing	Miling Guimont	Christine Hail
Teresa Dempsey	Melissa Ellis	Reiko Ellis	Caleb Getty	Suzette Guimont	Anne Heimbucher
Dina Denardis	Catrena Elmore	Valer Enea	Kathleen Gettys	Ann Gulley	Barbara Hein
Peggy Denbo	Valer Enea	Jeanne Engel	Sandra Gettys	Maureen Gunderson	Shauna Heinen
Joan Denman	Liliana Engel	Marianne England	Jennifer Geyer	Barita Gupta	Pamela Helgren
Dina Denne	Renee Englen	Reino Englen	George Gielen	Julie Gurke	Heidi Heller
John Dennis	Kir Enoch	Bruce Entrikin	Stacia Giesick	Cathryn Gustafson	Janet Hellwig
Verna Dennis	Louise Epperson	Wendy Francis	April Gilbert	Rhonda Giesen	Diana Helms
Kathy Depies	Robin Ercanbrack	Paul Frank	Sandra Gilbert	Kimberly Guy	Nicole Helms
Marianne Depoy	Theresa Ernst	Rita Frankel	Marlene Gilbertson	Alma Haak	Donna Heitzell
Laurie Deschier	Theresa Erps	Julie Franklin	Thomas Gilbertson	Inga Habada	Nina Hempfield
Linda Deslauniers	Maria Escalante	Scott Franklin	Denise Gillespie	Eugenia Hachenberg	Luann Henderson
Michelle Dess	Yamira Escobar	Shauna Franklin	John Gilliam	Frank Hackett	Vivian Henderson
Emily Dettre	Janie Espindola	Nicole Frank	Laurie Gilliam	Carole Hadnot	Willette Henderson
Marissa Devincnt	Helen Espinoza-Tovar	Theresa Frasher	Diane Gilmore	Cheryl Haffner	Naheisha Hendricks
Carol Devine	Elizabeth Essex	Suzanne Frasson	Lance Gilmore	Kay Hageman	Michelle Hendry
Tammy Devries	Jennifer Estad	Mollie Frawley	Nancy Gilmore	Lori Hager	Charles Hennekens
Vicki Diamond	Marilyn Estep	Brent Frazier	Katy Ginley	Robyn Hale	Dawn Hennon
Lizet Diaz	Patricia Fredette	Terri Frazier	Rosemarie Giorgio	Melanie Haley	Kristin Hennon
Maribel Diaz	Deborah Fredricks	Kelly Frederick	Deborah Girard	Bridget Hall	Elizabeth Henry
Laura Dickenson	Michelle Etheridge	Patricia Fredette	Helen Gittemeier	Christopher Hall	James Henshaw
Carol Dickinson	Dana Evans	Deborah Fredricks	Nela Gladys	Margaret Hall	Darla Hensley
Valera Dickinson	Mandie Evans	Ronald Freedman	Linda Glazner	Marisha Hall	Mary Herber
Linda Dickson	Suzanne Evans	Catherine Freeman	Steven Glick	Shaletha Hall	Angelica Hernandez
Dawn Dicorte	Kathleen Everitt	Ken Freeman	Catherine Glover	Sharon Hall	Glyden Hernandez
Tammy Diener	David Everly	Melinda Freeman	Rebecca Glover	Kristen Hambricht	Melissa Hernandez
Ann Dillier	Nicole Ewing	Shaneeka Freeman	Antoinette Goeling	Maryann Hamilton	Theresa Hernandez
Stephanie Dimmings	Elizabeth Ezzell	Sandi Fretmel-Heim	Edwilda Gomez	Vicki Hamilton	Carmen Hernandez-Cortes
Theresa Dinardo	Laura Fabbri	Lori Freie	Linda Gomillion	Nora Hamlin	Deborah Herod
Tam Dinh	Valeria Fabbri	George Freudenberg	Michael Gonzales	Sandra Hammel	Elizabeth Herrberg
Pamela Dinsmore	Rachel Faber	Catherine Frick	Jose Gonzalez	Wendy Hammel	Michelle Herren
Susan Dilus	Diane Fain-Anderson	Kenneth Frick	Maria Gonzalez	Sandra Hammock	Mayumi Herrera
Gamble Dixon	Maribel Falduto	Ingrid Friedrich	Sheila Gonzalez	Bobby Hammond	Nancy Herrold
Harriett Dixon	Diane Farley	Jenny Frimmer	Denise Joan Good	Susan Hammond	Elizabeth Hetherington
Yvette Dixon	Judith Farling	Tammy Froseth	Eddie Goodwin	Frieda Hamner	Matthew Heuston
Richard Dodds	Brenda Farrier	Natasha Frosnyuk	Susan Goodwin	Chester Han	Laura Heywood
Karen Doering	Yulia Faubel	Melissa Frost	James Randy Gore	Sang Han	Sharon Hickey
Janine Doezie	Rick Faulkner	Erin Frye	Kristene Gore	Arthur Hanley	Shimine Hicks
Kathleen Doiron	Cristine Fazenbaker	Irene Fulk	Pamela Gore	Teresa Hansberry	Ty Anthony Hicks
Lisa Donaldson	Jessica Federico	Liberty Fullon	Daniel Gormley	David Hansen	Bridget Hicks-Morris
Michael Donnelly	Diane Feeney	Brenda Fulton	Jeanne Goshen	Sheila Hansen	Robert Higby
Denise Donovan	Carolyn Fees	Terry Fung	Sarah Gotthard	Victor Hanson	Tiffani Hightower
Timothy Donovan	Crystal Felder	Regina Felipe	Frank Goulart	Wayne Hanson	Melissa Hildebrand
Patricia Doran	Evelyn Felice	Raven Femmore	Todd Grady	Laura Harbert	Becky Hill
Gregory Dorn	Elizabeth Ferguson	Chastity Gadois	Duane E Graf	Karletta Harbin	Christie Hill
Laurie Dorr-Craig			Michael Graham	Marcia Harden	Cynthia Hill
Randall Dorshorst				Mike Hardin	Deborah Hill
Martha Dotson					Deonne Hill
Jennifer Doub					
Sandra Dougherty					
Allison Douglas					
Donna Dowler					
Erica Downs					
Donna Doyle					
Julie Doyle					
Anita Drager					
Tresa Drake					
Dwayne Dressler					
Amanda Driver					
Nancy Drude					

Judy Hill
Karen Hill
Kimberly Hill
Patricia Hillestad
Donna Hilliard
Nikki Hilton
Rosemary Himuro
Kim Hines
Manish Hingorani
Judith Hirsch
Deborah Hodges
Ronald Hodges
Valerie Hodges
Angela Hoeger
Beth Hoffer
Lisa Hoffman
Mary Hoffman
Joan Hofmann
Kathleen Holden
Pamela Holden-Webber
Tammy Holder
Loretta Holgate
Debra Holland
Lydia Holland
Jerome Hollerbach
James Holman
Jovanna Holman
Cheryl Holmes
Daphne Holmes
Krystal Holtzhus
Carol Holtz
Anita Holtzman
Ronald Holyfield
Doug Homa
Christina Hommel
Kathryn Honaker
Richard Hood
Gloria Hooker
April Hooser
Cathleen Hopkins
Lisa Hopkins
Kathleen Hoppe
Theresa Horace
Julie Horak
Patricia Horan
Karen Horlacher
Patricia Horne
Wanda Horne
Brad Horner
Seward Horner
Juanita Horsey
Carla Horton
Tammy Horton
William Horton
Stephen Horvat
Linda Horvath
Alison Houston
Abbey Howell
Sharon Howel
Karen Howanestine
Daryl Howett
Stephen Howry
Darcy Hoyes
Tamra Hoyt
Hung Hsieh
Lynn Huber
Nancy Huber
Robert Huber
Christine Huddleston
Kathleen Huff
Dennis Huffline
Erin Huggard
Colleen Hughes
Lori Hughes
Kristin Huizenga
Amanda Humphrey
Barbara Humphries
Aleta Hunter
Conchetta Hunter
Pamela Huntley
Valerie Hurst
Joan Hussey
John Hutchinson
Lisa Hutter
Roger Hyde
Heather Hyland
Lisette Iglesias
Leslie Ihrie
Lorina Ines
Terri Ingram
Alvin Irby
Patricia Irvin
Angela Isgro
Russell Isgro
Alia Itkin
Patti Ives
Ronald Iwinski
Darlene Jackson
Debra Jackson
Erica Jackson
Jennifer Jackson
Pamela Jackson
Ruth Jackson
Sarah Jackson
Tahilia Jackson
Timothy Jackson
Wanda Jackson

Deborah Jacobs
Linda Jacobs
Robert Jagelski
Carolyn Jankowski
Connie Janzen
Michelle Jarquin
Elizabeth Jarratt
Kelly Jarvis
Ryan Jeffords
Elizabeth Jeitema
Jeffrey Jenkins
Karen Jenkins
Jacqueline Jennings
Sheeja Jensen
Laura Jerde
Joann Jessop
Heather Jessup
Sung-Hee Ji
Carmen Jimenez
Karla Jimenez
Miranda Jinnakin
Aric Johnson
Becky Johnson
Ben Johnson
Carol Johnson
Kathleen Johnson
Edna Johnson
Gerald Johnson
Gina Johnson
Jacquelyn Johnson
Judith Johnson
Kendra Johnson
Linda Johnson
Mary Catherine Johnson
Renée Johnson
Rita Johnson
Roberta Johnson
Stephen Johnson
Vanessa Johnson
Vickie Johnson
Welford Johnson
Wendy Johnson
Sharon Joiner
Lewis Jones Ponce
Angela Jones
David Jones
Deborah Jones
Deirdre Jones
Forest Jones
Jeanette Jones
Justin Jones
Kerrian Jones
Michele Jones
Nanica Jones
Preston Jones
Rechandra Jones
Ricky Jones
Victoria Jones
Michele Jones-Moseley
David Jordan
Pamela Jordan
Shelley Jore
Eileen Jorgensen
Marie Jorgensen
Adele Joseph
Barji Joshi
Anne Juangango
Bill Juermann
Irene Jurek
Candace Jurgielewicz
Lois Kahl
Melissa Kamm
Janet Kamperfer
David Kane
Candace Kannaday
Carole Kantor
Sue Kaniz
Lia Kaplan
Vana Karaminassian
Gail Karimian
Anthea Kari
Constance Kasai
Robin Katen
David Kau
Brian Kedik
Karen Keenan
Deana Kees
Mary Keister
Faith Keith
Jessica Kellenberger
Erin Kirby
Judith Keller
Melissa Kelley-Speed
Lisa Kelliher
Alicia Kelly
Dorothy Kelly
Mark Kemmerling
Jessica Kemp
Julie Kempkes
Lillie Kendrick
Carolyn Kennedy
Keoketh Keosombath
William Keough
Sandra Kerley
Penny Kerley-Smith
Sandra Kerr
Linda Kesler

Mali Kessler
Mary Kessler
Pamela Kessler
Sheri Kessler
Claudia Kettrick
Usman Khan
Behnaz Khandan
Lisa Khristov
Jaimathie Khusal
Mary Kiehl
Doreen Kiernan
Karen Kiessling
Judith Kile
David Kim
Joan Kim
Mak Im Kim
Young Kim
Nancy Kimbrell
Oscar Kimbrough
Karen Kimbrough
Paula Kimery
Jeffrey Kimmich
Cecilia Kimura
Linda King
Elaine Kirby
Jessica Kirk
Bryan Kirkpatrick
Steven Kirwan
Dana Kisel
Margaret Klein
Catherine Kleinschmidt
Carrie Klembara
Linda Klingler
Martin Klitzner
Heather Klock
Tommy Klug
Pamela Knaresboro
Mary Sue Knecht
Mary Kneel
Jill Kniffin
Diane Knight
Howard Knight
Mary Fran Knight
Christine Knolman
Sandra Knudsen
Silas Knudsen
Anthony Ko
Kristy Kobayashi
Jennifer Koehnke
Deborah Koenig
Sherry Koepke-Popovich
Karl Koerner
Catharina Kohler
Kerian Koizumi
Nancy Koken
Crystal Kolakowski
Andrea Kolder
Robert Konell
James Konenkamp
Patrice Konstanty
Natalie Koob
Jennifer Kornacki
Laura Kortokraz
Christina Korzun
Alma Kosmann
Jamie Kowalczyk
Mary Ellen Kozeluh
Regina Kraicek
Bonnie Kraisinger
Diane Kramer
Kellie Krasinski
Patricia Krause
Amy Krietmeyer
Janet Kriho
Cynthia Kuczkowski
Vera Nadine Kuhl
Catherine Kuhn
Andrea Kuntz
Sylvia Kurash
Ami Labrecque
Harvey Lacy
Viola Lafaille
Tania LaFuenta
Lorraine Lagan
Danette Laguardia
Shamika Lake
Thanh Lam
Tien Lam
Denise Lamanna
Sara Lambkin
Traci Lamer
Charlotte Lamp
Rita Lamparyk
Rita Lancaster
Laura Landen
Jeffrey Lane
Sue Lane
Jennifer Lange
Renée Lange
Michelle Laputz
Rebecca Lara
Mary Ann Laraia
Nancy Larreau
Jesse Larrison
Meirena Larsen
Ann Larson
Nancy Larson

Jennifer Lastiri
Stephen Lataxes
Brenda Laughlin
Jose Laureano
Corinne Lavinder
Petro Lawriw
Naomi Lawson
Sheryl Lawson
Tara Lawyer
Diane Lay
Jerry Layton
Patricia Le Penske
Yen Nguyen Le
Yenny Ngoc Le
Karen Leach
Diane Leachman
Luann Leaders
Karen Leak
Martha Leal
Dawn Lear
Nancy Leblanc
Sharon Lecease
Dawnmonique Lee
Mary Ann Lee
Penny Leek
Kimberly Leetzow
June Lefave
Deborah Lefort
Shawn Lehr
Don Leichhardt
Nancy Leingang
Carolyn Leishman
Heath Lemoine
Marlene Lemon
Ana Lemus
Karen Lenhart
Anna Lennon
Diana Lentz
Deborah Lenz
Kristine Lenza
Gaylene Leonard
Kris Leonard
Marilyn Leonard
Martin Leonard
Eric Leones
Charlene Lester
Kerry Leuty
Debra Lewars
Amber Lewis
Andronika Lewis
Cheryl Lewis
Darlene Lewis
Kesia Lewis
Theresa Lewis
Cynthia Lewter-Brown
Diane Lietzau
Joyce Lifshitz
Dawn Liggins
Leslie Limmer
Karen Lindner
Stephen Lindsay
Charlene Lindsey
Karen Lindsey
Stefanie Lindsey
Kerri Lindstedt
Barbara Link
Joan Linn
Damara Linneman
Delberta Lipscomb
Cynthia Little
Julie Little
Carol Littlefield
Christine Livingston
Julia Livingston
Kirstyn Livingston
Saniea Livingston
Gloria Llamas
Jennifer Lloyd
Kathleen Lockaby
Cynthia Lockamy
Joyce Lockhart
Debbie Loe
Barbara Loeffler-Ortiz
Jacqueline Logie
Neil Logsdon
Sue Logsdon
Roxane Lombardi
Jewel London
Carlos Londono
Jack Long
Janet Long
Keith Long
Marc Long
Marcia Long
Mary-Therese Long
Tony Longoria
Tammy Lonowski
Etheliza Lontoc
John Lopes
Leticia Lopez
San Juanita Lopez
Sherry Lopez
Crystal Lorah
Crystill Lorenzen
Angela Lorschough
Raemle Loveless

Sam Lovingood
Bernandeth Lowe
Diane Lowe
Eaine Lowenstein
Jeffery Lowman
Tonya Lowrey
Adam Lu
Lorie Luce
Edward Lugo
Paula Luhman
Patti Lummus
Karen Lundellus
William Lundin
Phyllis Luttreil
Kevin Luu
Sabrina Ly
Thanh-Van Ly
Luz Lykins
BJ Lyle
Patricia Lynch
Roxanne Lynch
Anne Lyng
David Lynn
Teresa Lynn
Kristine Lyon
Pamela Lyon
Christopher Lyons
Kathy Lyons
Margaret MacDonald
Judith MacDougall
Gregory Macera
Donna Macisac
Mary Mackey
Dana Madden
Angela Maddox
Sharon Madrzykowski
Adriana Magana
Annie Magee
Mark Alan Magee
Janice Magnusson
Mary Mahan
Traci Mai
Mary Main
Nina Maisonet
Ann Major
Mary Jane Major
Andrea Malcolm
Alberto Maldonado
Imran Malik
Roberto Mallo
Anne Maloney
Ashley Maloney
Jessica Mamer
Janet Manning
Judy Mannon
Jacqueline Manuel
Stephanie Manuel
Jill Manz
Deirdre Manzari
John Manzoilla
Pamela Marano
Chad Marceaux
Myra Marcial
Silvia Marinescu
Cathleen Marion
William Markille
Michelle Markman
Nancy Marks
Annetta Mariow
Abigail Marquez
Renée Marschall
Jay Martin
Kenneth Martin
Shari Martin
Shelley Martin
Brenda Martinez
Christen Martinez
Juanita Martinez
Melissa Dee Martinez
Tino Martinez
Nilda Martinez-Rodriguez
Elissa Martins
Staci Marvin
Tiffany Masarik
Leah Mason
Carol Massey
Rekha Mathai
Susan Mathews
Brenda Matthews
Barbara Mattson
Toni Maupin
Donna May
Subrina Mayes
Cheryl Mayforth
Janice McCabe
Kathy McCaffery
Jennifer McCaig
Patti Sue McCarty
Anthony McCash
Charlotte McCleery
Karen McCleery
Scott McCcloud
Linda McCorkle
Lin McCormick
Therese McCorquodale
Margaret McCoskey
Mary McCoy

Suzanne McCrimmon
Annette McCulley
Lori McCully-Butcher
Yonnie McDaniel
Sandra McDaniels
Lois McDermant
Lorraine McDermott
Michael McDermott
Sandra McDermott
Melissa McDole
Gloria McDonald
Ilene McDonald
Jane McElroy
Jennifer McElroy
Glince McElveen
Donald McFarlane
Peggy McGahagan
Margo McGivney
Charlene McGrath
Joann McGrath
James McGraw
Nicole McGregor
Maureen McGuire
Dian McIlwain
Aaron McKay
Linda McKenny
Barbara McKevitt
Michael McKevitt
Joanie McKinlay
Lisa McKinney
Dale McLaughlin
Yvonne McLin
Christine McMahon
Kenneth McMahon
Mary McMeans
Joanne McMillan
Joyce McMorris
Dennis McMullen
Jamie McNew
Cindy McQuillin
Karen McRea
Shannon McWilliams
Amy Meadows
Carol Meadows
Christie Meagher
Leanne Means
Christopher Medina
Lori Medina
Marcia Medina
Pamela Medina
Roni Meese
Julie Meer
Theresa Mehler
John Meier
Koko Mekdara
Edna Melendez
Vicki Melton
Paul Melvin
Gilbert Mena
Jadell Mendez
Florie Mendolia
Michelle Menendez
Stephanie Mengel
Barbara Menkhaus
Juan Meraz Jr.
Carolina Meraz
Arnel Mercado
Christine Mercado
Gail Merced
Maria Merced-Ramirez
Elen Merick
Liamia Merlo
Janice Meron
Melinda Merrick
Cheryl Merritt
Mary Merritt
Judy Merseis
Michelle Mescall
Crystalyn Messer
Kimberlyn Messer
Laura Messer
Kathleen Messimer
Kelly Messmer
Cynthia Metzgar
Lori Meulners
Dena Meyers
Dianna Michael
Nicole Michalski
Paul Michalski
Amy Middlebrooks
Kelli Middleton
Lisa Mihara
Carrie Mikesch
Karen Miksic
Ruth Milbee
Beverly Miles
Judith Miles
William Miles
Kevin Millard
Maxine Millard
Amy Miller
Angela Miller
Cheryl Miller
Colleen Miller
Karen Miller
Kristen Miller
Lauren Miller

Leticia Miller	Gretchen Myers	Karen O'Rourke	Pamela Piper	Whitney Rehm	Malin Ruffino
Marie Miller	James Myers	Cathy Orr	Amber Phippen	Darrin Reichle	Mishelle Ruhkala
Pamela Miller	Joyce Myers	Robin Ortega	Patricia Phippen	David Reid	Angela Rush
Patricia Miller	Bryce Myngaheer	Jessica Ortiz	Pachez Pirtle	Leslie Reid	Michon Russ
Pauletta Miller	Joanne Nadeau	Mayra Ortiz	Sharon Pitts	Serena Reiff	Amy Russell
Pauline Miller	Amy Nakayama	Robert Ortiz	Laura Pivonka	Melissa Reillo	Barbara Russell
Richard Miller	Jeanne Napier	Susan Orzolek	Saundra Pivinski	Ruth Reilly	Burnis Russell
Ruissa Miller	Christine Naugle	Elizabeth Osborn	Jane Plimack	Marilyn Reimann	Paul Russell
Susan Miller	Stephanie Nault	Derick O'Sullivan	Michele Plocki	Cheryl Reineck	Joan Russell
Tina Miller	Janet Nauman	Kimberly O'Toole	Christine Plowman	Karen C. Reinhardt	Amy Russo
Victoria Miller	Mark Nava	Lauren Ott	Cory Plummer	Karen Reinhardt	Tricia Rutherford
Cathleen Miligan-Gilman	Anthony Navarro	Anne Outlaw	Ronald Plute	Victoria Rei-Ristow	Mary Ruvalcaba
Deborah Mills	Patricia Navarro	Julie Overcash	Linda Potche	Betty Reither	Janice Ryals
Patricia Milmine	Yessenia Navarro	Trevia Overstreet	Stacey Podgorski	Ardyth Renden	Joni Ryan
Patricia Mimms	Theodore Neale	Jennifer Oviatt	Silvia Poe	Tina Renfro	Terry Ryan
Malanie Minister	Cynthia Neary	Trenton Owen	Connie Pohlman	Tom Renick	Marzena Rybicki
Jessy Miot	Beverly Negrete	Jessica Owens	Ellen Poleski	Mary Rennick	Roger Ryon
Laura Mireles	Joanne Nehls	Marcia Owens	Jodi Polston	Brian Renshaw	Dianna Rysticken
Larry Missing	Lee Neidhart	Sheryl Owens	John Pompei	Ellen Renslev	Joel Sabaiza Jr
Carolyn Mitchell	Shanna Neis	Tanna Owens	Patricia Pomper	Antoinette Reyes	Lisa Sabye
Janet Mitchell	Gary Nelson	Julie Ozier	Elia Ponce	Charles Reyes	Pamela Sakai
Laura Mitchell	Rue Nelson	Gail Pacifico	Carol Poniewaz	Eleonor Reyes	Amanda Saleh
Lavonne Mitchell	Tony Nelson	Pamela Padgett	Dorine Poole	Hortensia Reyes	Tonya Salley-White
Mary Mitchell	Tonya Nelson	Ann Page	Staria Pooley	Heather Reynolds	Kadhin Salman
Aboy Mittemann	Beth Nemeth	James Pagel	Carletta Pope	Lisa Rhea	Patricia Samuels
Tamara Mittelstadt	Nicky Nestor	Joanne Palladino	Danna Pope	Gail Rheume	Jennifer Sanbet
Kayleigh Mitterholzer	Susan Neuhaert	April Palmer	Deborah Popovich	Nina Rhodes	Alicia Sanchez
Lisa Mobley	Theresa Neuhaus	Joel Palmer	Randy Porco	Joel Rhynier	Elaine Sanchez
Laurie Modrall	Kimberly New	Linda Palmer	Gloria Porter	Megan Riccobuono	Milagros Sanchez
Christy Mohar	Nancy Newberry	Cristina Paralejas	Tamora Posey	Arthur Rice	Sandra Sanchez
Jasmin Molina	Merissa Newell	Yolanda Paredes	Susan Post	Sharon Rice	Veronica Sanchez
Jenny Moline	Dana Newinsky	Elizabeth Parente	Carli Potter	Susan Rice	Annette Sanchez-Schafer
Deborah Moman	Vicki Newmaker	John Parker	Joe Potts	Sharon Ricely	Cathy Sanders
Cheryl Monroe	Gwendolyn Newsom	Patricia Parker	Stacy Povlin-Lambert	Jennifer Rich	Rose Sanders
Claudia Montes De Oca	Diane Nghiem	Sandra Parra-Vogler	Kathleen Powell	Karly Rich	Therese Sanders
Laura Montoya	Jacklyn Ngo	Mary Parrinello	Lori Powell	Aaron Richard	Rachael Sandkamp
Lawrence Montoya	Johnny Ngo	Arlene Pasqua	Phonisa Powell	Chariene Richardson	Arti Sandoval
Christopher Moody	Vivian Ngo	Christina Passmore	Sandra Powell	Erin Richardson	Dae Sands
Carolyn Moore	Chau Nguyen	Maria Patag-Galang	Toni Powell	Jennifer Richardson	Marla Sands
Judith Moore	Sam Nguyen	Rajeshkumar Patel	Kathy Powers	Mercario Richardson	Lauren Sanford
Katherine Moore	Tammy Nguyen	Many Patire	Kate Powers-Piewe	Sarah Richardson	Shasta Sanneman
Kay Moore	Lorraine Nicholas	Patricia Patrick	Vasanthakumari Prammaganam	Tina Richardson	John Santana
Ronda Moore	Philip Nichols	Ralph Patterson	Cynthia Pratt	Shirley Rickert	Susanah Santangini
Susie Moore	Philipp Nicol	Denise Paul	Cynthia Preist	Katrina Rico	Eric Santiago
Cassandra Moore-Bailey	Jeffery Nicoletti	Ginger Paulk	Teresa Preiss	Elizabeth Ridings	Maria Santiago
Steve Mootz	Mark Niedert	Michele Payment	Ingrid Prentice	Kristina Riens	Nichole Sapp
Anna Morales	Ruth Ann Niedert	Diane Payne	Laetonia Pressley	Jane Rife	Dan Saraz
Lorena Morales	Debra Nieto	Marcia Payne	Elizabeth Prestin	Lauren Riggs	Jason Sardis
Miriam Morales	Josue Nieves	Micheal Payne	Gary Price	Judith Rinderle	Teresa Saunders
Allison Moran	Moses Nieves	Teresa Peace	Lhiquita Price	Jerilyn Ann Ring	Thomas Savage
Rhonda Moran	Joanne Niglio	Michelle Peaceam	Lou Price	Judith Risley	Michael Saverien
Natalie Morehouse	Stephanie Nimblett	Jesse Pease	Teresa Price	Frances Rittenhouse	Marianne Sawaya
Bianca Morejon	Stephen Nolan	David Peavy	Many Prideaux	Rebecca Riva	Rose Schaaf
Ana Moreno	Eric Norful	Heather Peck	Cynthia Pritchard	Guadalupe Rivaldes	Dina Schaeffer
Maria Moreno	Joshua Norman	Freddy Pedersen	Diane Pritchard	Irene Rivera	Dollinda Schaffer
Sandra Moreno	Jo North	Roxie Pedroli	Cristina Procta	Juan Rivera	Yvonne Schautteet
Donna Morgan	Kathryn Norton	Juan Pedroza	Marcellas Proctor	Moses Rivera	Victoria Schaeckel
Dorothy Morgan	Gary Nosonovsky	Karla Pedroza	Arlene Propt	Maritza Rivero	Mary Scheel
Jaclynne Morgan	Denise Nostin	Twila Peitz	Paula Pruitt	Patricia Roark	Nicole Schell
Jill Morgan	Shirley Nouter	Felecia Pellam	Yvette Pryor	Velisa Robbins	Megan Schemmel
Joan Morgan	Debra Novak	Sarah Pelzi	Dominika Pukay	David Roberts	Aaron Schenck
Jody Morgan	Margaret Nowak	Kim Pemberton	Nicole Rafuse	Jennifer Roberts	Katherine Schieble
Kent Morgan	Tim Nowlin	Julie Ponce Pena	Jake Putzler	Nicole Roberts	Janet Schiell
Linda Morgan	Kathy Nultemeier	Michael Pena	Abdulla Qudrat	Phyllis Roberts	Sharon Schiera
Patricia Morgan	Keitha Nunn	Tawn Pena	Nooria Qudrat	Tara Robertson	Gretchen Schild
Rachael Morgan	Peggy Nyman	Many Pence	Blanca Quiles-Marrero	Crystal Robinson	Teresa Schliem
Rebecca Morgan	Linda O'Bayley	Connie Pendley	Elizbeth Quinn	Lisa Robinson	Beth Schlip
Robin Morgan	Carol Oberley	Marjorie Penebacker	Theresa Rabinck	Margaret Robinson	Catherine Schmelz
Tammy Morney	Brandon O'Brien	Wilma Pennell	Pamela Raboin	Sheryl Robinson	Elaine Schmidt
Claudia Morrell	Christine O'Brien	Anne Penrod	Susan Radzwickas	Steven Robinson	John Schmidt
Joseph Morris	Edith Ochoa	Ludinda Perey	Vicki Ragdale	Theresa Rocca	David Schmitz
Paula Morrison	Mayra Ochoa	Rose Perez	Jennifer Raiche	Maritza Rodriguez De Perea	Deborah Schmollinger
Rosemary Morris	Eileen O'Connell	Tyler Perkins	Constance Raines-Kriese	Elizabeth Rodriguez	Michele Schneider
Jean Morrow	Jill O'Connor	Tina Perran	Patricia Raison	Michelle Rodriguez	Alison Schoepf
Sonya Morton	Joseph O'Dell	David Peterson	Ganesan Rajaraman	Sylvia Rodriguez	Cindy Schopfer
Daryl Moxbey	Joseph O'Donnell	Hazel Peterson	Eileen Ramallo	Gustavo Rodriguez-Bacardi	Linda Schoppe
Denise Mouglin	Judith O'Donovan	Jacqueline Peterson	Diana Ramirez	Gail Rogers	Debbie Schreck
Annette Moyer	Kimberly Offutt	Jeanne Petrie	Manuel Ramirez	Ann M Rohlf	Lisa Schreiber
Cheryl Moylett	Colleen O'Halloran	Jaime Petrijanos	Rosalva Ramirez	Elena Rojas	Marie Schroeder
Carmen Muchacho	Karen Ohanesian	Kimberly Peynardo	Lawrence Ramos	Micheline Rojas	Ming Schu
Janet Mudek	Lisa O'Hehir	Paula Pezzano	Julie Randleman	Shari Romain	Alicia Schubert
Kathrine Mueller	Rhonda Okolo	Corrina Phillips	Anthony Randolph	Hortensia Roman	Jane Schuck
Debra Muir	Rachel Olcheski	Dana Phillippi	Renee Rangel	Marianna Roman	Mary Ann Schuerman
Marilyn Mule	Tina O'Leary	Barbara Phillips	Kenia Rao	Nicholas Romano	Susan Schuknecht
Joyce Mullin	Sandra Olesen	Donna Phillips	Venice Rashford	Evelyn Romero	Tessa Schultz
Bridget Mundy	Christinda Oliphant	Peggy Phillips	Michael Rasmussen	Cariton Rood	Tracie Schultz
Jeanette Mungcal	Valerie Oliver	Vanessa Phillips	Nicole Rasmussen	Kerrie Ropp	Laura Schumacher
Alexandra Muniz-Dejesus	Sharon Ollie	Phiney Phinny	Scott Rasmussen	Kimberly Roque	Nancy Schumacher
Jana Munoz	Heather Olmsted	Pane Phomphak	Tina Rattigan	Carmen Rosales	Rhonda Schutz
Norma Munoz	Leslie Olmsted	Linda Pica	Roger Rawlings	Melanie Rosario	Dana Schwartz
Gloria Munson	Samantha Olmsted	Kelly Pickel	Thelma Raymond	Connie Rose	Laura Schwartz
Patricia Munz	Helen Olsen	Debe Pickering	Margaret Reagan	Laura Rosenbaum	Joann Schweigert
Theresa Murkey	Michele Olsen	Don Pickering	Hazel Rebadulla	Marina Rosenfield	Nicholas Schweizer
Ann Murphy	Denise Olson	Fabio Pico	Shruti Redcy	Mary Rossi	Richard Schweppe
Barbara Murphy	Joyce Olson	Juliana Picon	Jeffrey Redifer	David Rothwell	Dwanda Scott
Kimberly Murphy	Kimberly Olson	Henry Pierce	Lisa Redifer	Vicki Rottman	Kelly Scott
Mary Murphy	Ledonna O'Neal	Michelle Piercy	Elizabeth Reed	Gwen Rowe	Kristy Scott
Patricia Murphy	Don Oggenorth	Kristen Pierson	Kelly Reed	Tami Rowe	Linda Scott
Patricia Murray	Lynn Oppy	Sharyn Pimpinella	Shirleen Reed	Janine Roybal	Sarah Scott
Allison Muscant	Gredia Oquendo	Gerard Pierre-Trettel	Marco Reese	Rachel Royle	Greg Scovel
Shannon Mutz	Jonathan Orense	Gladys Pinover	Tiffany Reese	Susan Rozell	Letasha Screen
Curt Muyres	Patricia O'Riley	Gloria Orme	Valerie Reese	Valerie Rozestraten	Shugie Scroggin
Alexander Myachin	Gail Ormiston	Anna Piper	Rebecca Reeves	Paula Rozplochowski	Kimberly Scurlock
Ann Myers			Carmela Rega	Janet Rubo	Debra Seals
Debra Myers					Charles Sears

Deanna Sebesta
Elizabeth Sedillo
Kenneth Selensky
Robert Seliskar
Tracy Sellers
Roxane Semic
Margaret Sender
John Sendlosky
Betty Seng
Veronica Serrano
Melissa Sessions
Carlos Severe Marcelin
Charita Severe
Mary Sevinsky
Angela Sewell
Scott Sexton
Sherry Shaffer
Meghana Shah
Mukundray Shah
Barbara Shane
Lisa Shapiro
Lisa Sharkey
Renu Sharma
Ashley Sharp
Krista Sharp
Sheryl Sharpe
Cynthia Sharrette
Lynda Shaw
Dylan Shaw
Lynn Shaw
Shenika Shaw
Beverly Sheetz
Diane Shefveland
Brenda Sheppard
Mary Sherman
Matthew Sherman
Kristine Sherrard
Susan Shewczyk
Sheila Shidlofsky
Virginia Shields
Griselle Shinker
Margaret Shinn
Nancy Shinn
Angela Shipp
Maxim Shishin
Shahrooz Shomali
Amy Shoots
Lila Shores
Pamela Shores
Jennifer Short
Sandra Short
Leslie Shoup
Catherine Showers
Jerald Sia
Katherine Siegel
Jolene Silbernagel
Lisette Silva
Nicole Silva
Toni Silva
Christopher Simants
Christine Simler
Kevin Simler
Shena Simmons
Patricia Simmons
Susan Simmons
Amy Simpson
John Simpson
Liliana Sinclair
Susan Sineni
Kathleen Sinn
Catherine Siver
Elizabeth Sizemore
Mirela Skaka
Cathy Skebo
Lesley Skipper
Deborah Skoglund
Ashley Slate
Dolores Slavis
Lois Sloan
Mary Sloan
Jane Smerdeli
Arlene Smith
Catherine Smith
Christina Smith
Connie Smith
Cristine Smith
Debbie Smith
Debra Smith
Diana Smith
Ellen Smith
Emmely Smith
George Smith
Jean Smith
Jennifer Smith
Judy Smith
Kimberly Smith
Linda Smith
Lisa Smith
Lisa A Smith
Margaret Smith
Margaret Smith
Matthew Smith
Michael Smith
Nancy Smith
Rachel Smith
Robbin Smith
Rusty Smith

Sharon Smith
Tamara Smith
Vera Smith
William Smith
Julia Smythe
Nanisa Snooks
Anthony Snyder
Robert Snyder
Sherry Snype
Rae Sobabab
Nanette Socino
Anita Solano
Margaret Sommers
Khamnoi Somsavath
Mina Song
Lisa Sonka
Robbin Sonnenberg
Sandra Soriano
Michelle Sorrentino
Adele Spacher
Linda Spade
Lindsay Spain
Rebecca Sparger
Alma Spence
Karen Spence
Scott Spencer
Grigorianna Spenciu
Cathleen Spradley
Deborah Sprague
Pam Stur
Pamela St. Clair
Leane St. Peter
Kathryn Stack
Shelby Staffenson
Loretta Stafford
Darren Stahulak
Mary Stallworth
Hana Stara
Lori Staup
Kathy Steadman
Deborah Stears
Deborah Stebnitz
Mary Steffen
Latonya Stegall
Anna Steinberger
Jacquelin Steindl
Lindy Steiner
Tasha Steinkamp
Lianabel Stephenson
Philip Sterling
Bodee Stevanus
Gregory Stevens
Harriett Stevens
Stephanie Stevens
Lynn Stevens-Mitchell
Gayla Stewart
Susan Stewart
Ty Stewart
Nancy Stickley
Susan Stier
Jody Stiger
Laurie Stiggers
Donald Stobo
Cathy Stogel
Bill Stolte
Jacquelyn Stone
Paula Stone
Marianne Stone
Mary Stouch
Phillip Stowers
Ryan Stradley
Paula Straka
Penny Stratton
Douglas Strauss
Robin Strick
Katherine Stroh
Amy Stroud
Linda Stroud
Daria Strzesynski
Margaret Stutsman
Patricia Styles
Suriyakumar Subrahmanjan
Jungtheem Suh
Charlotte Sujeta
James Sullivan
Winifred Sullivan
Nandakumar Sundaresan
Sara Sundborg
Robin Surrey
Margaret Sutherland
Steven Sutherland
Nancy Swaim
Victoria Swankie
Kathy Swart
Monique Swartz
Michele Swearingen
Katie Sweeney
Kimberly Sweeney
Patrick Sweeney
Georgiana Sweetwater
Tracy Swift
Wendy Sykes
Debra Symon
Ladda Sysomvang
Valerie Szellung
Stephen Szuchy
Duane Szymanski
Michelle Szymczak

Cheryl Tadiello
Sara Taggart
Renee Taft
Alice Taniguchi
Joyce Tanillo
Myrna Tapounet
Irina Tarasenko
Angela Tarquinio
Michelle Tarr
Audrey Tart
Maryann Tartamella
Evelyn Tataje
Kimberly Tatiian
Colleen Tatom
Carolyn Taylor
Jean Taylor
Pamela Taylor
Sandra Soriano
Sherry Tedder
Shirley Teders
Gayle Tedford
Luan Teh
Joseph Teixeira
Suzanne Templeton
Sharon Terry
Mary Tevin
Michelle Thane
Rhonda Theis
Carla Thibault
Bradley Thiele
Alicia Thomas
Christopher Thomas
Danielle Thomas
Jennifer Thomas
Juli Thomas
Karen Thomas
Sonia Thomas
Christina Thompson
Mandie Thompson
Dianne Thompson
Tracy Thompson
Daniel Thunder
Linda Thurman
Tanya Thurman
Cynthia Tidwell
Anne-Marie Tierney
Douglas Tierney
Carla Tierno-Hogue
Debra Tilhof
Deborah Tillman
Jillian Tillman
Pamela Tillman
Dayna Timmins
Nancy Timura
Maureen Tinker
Patricia Tirado
Joseph Tirinzoni
Shirley Tirone
Lynnda Tobolski
Elizabeth Tocarcuc
Lisa Tokich
Laura Tolbert
Alicia Toledo
Haley Tolman
Meghan Tolman
David Tompkins
Holly Tompkins
Robert Tompkins
Quangthy Ton
Teresa Tong
Deborah Toole
Bertha Torres
Melissa Torres
Pamela Tortorici
Lisa Tortorici
Ronald Toth
Marion Tovar
Teresa Tracy
Dana Trainor
Minsela Trambitas
Cynthia Trammel
Christine Tran
Dung Tran
Gina Tran
Hung Tran
Huy Tran
Kiet Tran
Kim Tran
Steven Tran
Luyen Tran
Mary Traver
Kimberlee Travers
Susann Traxel
Roberta Treake
Courtney Trinh
Deborah Trinidad
David Trinka
James Tripp
Malgorzata Trojanowska
Marsha Trooper
Paul Troyer
Sharon Trudeau
Cecilia Trujillo
Jessica Trujillo
David Tucker

Andrea Tugander
Janice Tuggle
Alisa Tunstall
Norma Turkalp
Denise Turner
Gayle Turner
Martha Turner
Nancy Turner
Scott Turner
Tsmara Tyler
Lillie Tyson
Erica Ugalde
Rose Ung
Karen Updegraff
Lauren Upshaw
Corrina Urias
Kathleen Vaden
Lena Vakulich
Dana Valentine
Pamela Vales
Rhonda Van Cleve
Rhonda Van Meter
Sarah Vance
Sarah Vanderveen
Pang Vang
Linda Vanseth
Ingrid Van't Hof
Margareth VanVeen-Smith
Anastacia Varela
Cynthia Vargas
Sharonanne Vargo
Bettina Varner
Christine Varner
Eleonor Varner
Ellen Varner
Alice Vason
Susan Vassallo
Victoria Vasta
Amanda Vatter
Julie Vaughan
Beth Veeder
Amy Vega
Claudia Veira
Tina Vela
Stacy Velarde
Linda Velasquez
Liza Velazquez
Gladys Velez
Thomas Vermilya
Barbara Vernon
Renee Vick
Don Vidal
Osvaldo Barrera Vieyra
Kalouna Virachith
Jeanine Visser
Thuy Van Vo
Melissa Vogelman
Kathleen Voigtlander
Phyllis Volk
Kathleen Volpe
Christopher Von Arb
Karen Von Reichmuth
Betty Vosberg
Laura Voyles
Blanche Voyzy
Malissa Vrana
Clostina Vrba
Chris Vu
Katie Vu
Truc Vu
Donna Wade
Gina Wade
Sunny Wade
Traci Wade
Sharon Wagner Stewart
Lynette Wagner
Margaret Wagner
Margaret Wagner
Priscilla Waltek
Chadwick Walden
Joanne Waldron
Charlene Waley
Cathy Walker
Shayne Walker
Karen Walker
Kenyon Walker
Lynne Walker
Tara Walker
Julie Wallace
Linda Wallerstedt
Christopher Walsh
Brittany Walters
Karen Walters
Mary Walters
Eric Walton
Eric Waraksa
Leslie Warbrick
Stacie Ward
Vivian Ward
Milledge Ware
Geraldine Warne
Anna Warner
Angela Warren
Celina Warriner
Kim Washburn
Beverly Washington
Nelson Washington

Leticia Wasso
Sandra Wastler
Debra Watkins
Marcus Watkins
Mary Watkins
Erim Watkins
Cindy Watson
Daniella Watson
Stefani Watson
Zebulan Watson
Karen Watters
Cheryl Wayman
Patricia Weartz
Sandra Weaver
Anna Weaver
Claude Weber
Sherry Weber
Traci Webster
Karen Weimer
Patricia Weimert
Ashley Welch
Christine Welborn
Amy Wellman
Aynsley Wells
Beverly Wells
Cathy Wells
Susan Welsh
Karla Welte
Therese Weiler
Shawn West
Nancy Westberg
Kathryn Westlund
Patricia Weston
Paul Wexler
Lisa Wheeler
Robert Wheeler
Patricia Whisenant
Cynthia Whisman
Barbara White
James White
Jane White
Jeffrey White
Joann White
Kelly White
Laura White
Lynne White
Patricia White
Gordon Whitehead
Lee Whitehead
Marilee Whitehill
Elizabeth Whiting
Brad Whitley
Danielle Whitney
Einwen Whitney
Dianne Whitworth
Kristine Wileand
Patricia Wiecheki
Michele Wielde
Julie Wierick
Ted Wiese
Donna Wiggins
Mary Wiglus
Ronda Wiles
Debra Wilkerson
J. Nicole Wilkins
Carol Wilkinson
Harriet Wilkinson
Jonathan Wilkinson
Patricia Willett
Amanda Williams
Bernestine Williams
Carolyn Williams
Cheile Williams
Christina Williams
Dainer Williams
Holly Williams
James Williams
Judy Williams
Kelly Williams
Kerri Williams
Ladonna Williams
LaKendra Williams
Mizzi Williams
Opheila Williams
Patricia Williams
Penny Williams
Renarda Williams
Shannon Williams
Shirley Williams
Stephena Williams
Sherrie Williams-Leach
Nina Willis
Christina Wilson
Eileen Wilson
Heather Wilson
Henry Wilson
Kathleen Wilson
Latashia Wilson
Linda Wilson
Linda Wilson
Ryan Wilson
Sharon Wilson
Shirley Wilson
Sean Wiltson
Cindi Wimer
Gregory Winchester

Carol Winetrou
Candace Winter
Stafford Winters
Candy Winton
Dawn Wipf
Judith Wise
Kathleen Witherehl
Peter Wittig
Ron Wojciechowski
Cynthia Wojtkowski
Craig Wolfe
Linda Worn
Anita Woodard
Denise Woodard
Linda Woodling
Jennifer Woods
Kellie Woods
Resna Reneae Woods
Michael Wooliver
Judy Wootton
Amitabha Worcester
Jennifer Worth
Peter Worden
Deborah Wright
Donna Wright
Karen Wright
Kim Wright
Laurie Wright
Martha Wright
Marvie Wright
Patricia Wright
Shelley Wright
Charlotte Wrister
Pat Wrobel
Maricar Wuersch
Brian Wurst
Gaylan Wykes
Kathy Wynn
Gay Wysz
Donna Wysocki
Kelly Xiong
Richard Allen Yamin
Cheryl Yarnall
Kathryn Yarbrough
Lisa Yarish
Don Yates
Nawang Yeshopa
Lorna Yonan
Stacey Yonshige
Judith York
Stephanie Yost
David Young
Elizabeth Young
Jennifer Young
Katherine Young
Kristin Young
Susan Young
Pamela Youngblood
Kathryn Yutsai
Karen Zamudio
Melissa Zannis
Robert Zapata
Jacqueline Zaydel
Jami Zdanowicz
Omar Zegarra
Troy Zenzen
Joseph Zeppetella
Jihua Zhang
Bobbi Zdon
Yolanda Ziegler
Kevin Ziehr
Melissa Zientek
Tommie Zimmer
Heather Zimmerman
Timothy Zimmerman
Daniel Zipay
Julie Zook
Jynx Zorrilla
Zach Zuehlke
James Zurek
Lisa Zvyak

Alabama
Birmingham

Alaska
Anchorage
Fairbanks

Arizona
Phoenix

Arkansas
Fayetteville
Little Rock

California
Concord
Fresno
Irvine
Laguna Niguel
Los Angeles
Orange
Sacramento
San Bernardino
San Diego
San Mateo

Colorado
Colorado Springs
Denver

Connecticut
Hartford

Delaware
Wilmington

Florida
Coral Springs
Jacksonville
Lake Mary
Miami
Orlando
Pensacola
Tallahassee
Tampa

Georgia
Albany
Atlanta
Savannah

Hawaii
Hilo
Honolulu

Idaho
Boise
Pocatello

Illinois
Chicago
Marion
Mattoon
Peoria
Rockford
Springfield
Waterloo
Westmont

Indiana
Evansville
Fort Wayne
Indianapolis
Merrillville

Iowa
Cedar Rapids
Davenport
Des Moines
Fort Dodge
Sioux City

Kansas
Kansas City
Wichita

Kentucky
Lexington
Louisville

Louisiana
Baton Rouge
New Orleans

Maine
Portland

Maryland
Annapolis
Baltimore
Hagerstown
Rockville

Massachusetts
Boston
Springfield

Michigan
Detroit
Grand Rapids
Lansing
Troy

Minnesota
Austin
Brainerd
Duluth
Grand Rapids
Minneapolis

Mississippi
Gulfport
Jackson

Missouri
Columbia
St Louis

Montana
Kalispell
Missoula

Nebraska
Lincoln
Omaha

Nevada
Las Vegas
Reno

New Hampshire
Bedford

New Jersey
Cherry Hill
West Windsor
Whippany

New Mexico
Albuquerque

New York
Albany
Buffalo
Long Island
Syracuse

North Carolina
Charlotte
High Point
Raleigh

North Dakota
Bismarck
Fargo

Ohio
Cincinnati
Cleveland
Columbus
Toledo
Warren

Oklahoma
Oklahoma City
Tulsa

Oregon
Lake Oswego
Portland

Pennsylvania
Harrisburg
Philadelphia
Pittsburgh
Newton

Rhode Island
Providence

South Carolina
Columbia

South Dakota
Rapid City
Sioux Falls

Tennessee
Knoxville
Nashville

Texas
Austin
Dallas
El Paso
Fort Worth
Houston
Las Colinas
Lubbock
McAllen
San Antonio

Utah
Salt Lake City

Vermont
Barre

Virginia
Abingdon
Chesapeake
Fairfax
Fredericksburg
Glen Allen
Richmond
Roanoke

Washington
Brewster
Everett
Moses Lake
Mount Vernon
Richland
Seattle
Silverdale
Spokane
Tacoma
Wenatchee
Yakima

West Virginia
Charleston

Wisconsin
Amery
Black River Falls
Green Bay
Madison
Milwaukee
Wausau

Puerto Rico
Hato Rey
San Juan

CorVel Corporation

888 7 CORVEL

www.corvel.com/insight

CORVEL®